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A B S T R A C T
Background
Fibromyalgia is characterised by persistent, widespread pain; sleep problems; and fatigue. Transcutaneous electrical nerve stimulation
(TENS) is the delivery of pulsed electrical currents across the intact surface of the skin to stimulate peripheral nerves and is used
extensively tomanage painful conditions. TENS is inexpensive, safe, and can be self-administered. TENS reduces pain duringmovement
in some people so it may be a useful adjunct to assist participation in exercise and activities of daily living. To date, there has been only
one systematic review in 2012 which included TENS, amongst other treatments, for fibromyalgia, and the authors concluded that
TENS was not effective.
Objectives
Toassess the analgesic efficacy and adverse events ofTENS alone or added tousual care (including exercise) comparedwith placebo (sham)
TENS; no treatment; exercise alone; or other treatment including medication, electroacupuncture, warmth therapy, or hydrotherapy
for fibromyalgia in adults.
Search methods
We searched the following electronic databases up to 18 January 2017: CENTRAL (CRSO); MEDLINE (Ovid); Embase (Ovid);
CINAHL (EBSCO); PsycINFO (Ovid); LILACS; PEDRO; Web of Science (ISI); AMED (Ovid); and SPORTDiscus (EBSCO). We
also searched three trial registries. There were no language restrictions.
Selection criteria
We included randomised controlled trials (RCTs) or quasi-randomised trials of TENS treatment for pain associated with fibromyalgia
in adults. We included cross-over and parallel-group trial designs. We included studies that evaluated TENS administered using non-
invasive techniques at intensities that produced perceptible TENS sensations during stimulation at either the site of pain or over nerve
bundles proximal (or near) to the site of pain. We included TENS administered as a sole treatment or TENS in combination with
other treatments, and TENS given as a single treatment or as a course of treatments.
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Data collection and analysis
Two review authors independently determined study eligibility by assessing each record and reaching agreement by discussion. A third
review author acted as arbiter. We did not anonymise the records of studies before assessment. Two review authors independently
extracted data and assessed risk of bias of included studies before entering information into a ’Characteristics of included studies’
table. Primary outcomes were participant-reported pain relief from baseline of 30% or greater or 50% or greater, and Patient Global
Impression of Change (PGIC). We assessed the evidence using GRADE and added ’Summary of findings’ tables.
Main results
We included eight studies (seven RCTs, one quasi-RCT, 315 adults (299 women), aged 18 to 75 years): six used a parallel-group design
and two used a cross-over design. Sample sizes of intervention arms were five to 43 participants.
Two studies, one of which was a cross-over design, compared TENS with placebo TENS (82 participants), one study compared TENS
with no treatment (43 participants), and four studies compared TENS with other treatments (medication (two studies, 74 participants),
electroacupuncture (one study, 44 participants), superficial warmth (one cross-over study, 32 participants), and hydrotherapy (one
study, 10 participants)). Two studies compared TENS plus exercise with exercise alone (98 participants, 49 per treatment arm). None
of the studies measured participant-reported pain relief of 50% or greater or PGIC. Overall, the studies were at unclear or high risk of
bias, and in particular all were at high risk of bias for sample size.
Only one study (14 participants) measured the primary outcome participant-reported pain relief of 30% or greater. Thirty percent
achieved 30% or greater reduction in pain with TENS and exercise compared with 13% with exercise alone. One study found 10/28
participants reported pain relief of 25% or greater with TENS compared with 10/24 participants using superficial warmth (42 °C).
We judged that statistical pooling was not possible because there were insufficient data and outcomes were not homogeneous.
There were no data for the primary outcomes participant-reported pain relief from baseline of 50% or greater and PGIC.
There was a paucity of data for secondary outcomes. One pilot cross-over study of 43 participants found that themean (95% confidence
intervals (CI)) decrease in pain intensity on movement (100-mm visual analogue scale (VAS)) during one 30-minute treatment was
11.1 mm (95% CI 5.9 to 16.3) for TENS and 2.3 mm (95% CI 2.4 to 7.7) for placebo TENS. There were no significant differences
between TENS and placebo for pain at rest. One parallel group study of 39 participants found that mean ± standard deviation (SD)
pain intensity (100-mm VAS) decreased from 85 ± 20 mm at baseline to 43 ± 20 mm after one week of dual-site TENS; decreased
from 85 ± 10 mm at baseline to 60 ± 10 mm after single-site TENS; and decreased from 82 ± 20 mm at baseline to 80 ± 20 mm after
one week of placebo TENS. The authors of seven studies concluded that TENS relieved pain but the findings of single small studies
are unlikely to be correct.
One study found clinically important improvements in Fibromyalgia Impact Questionnaire (FIQ) subscales for work performance,
fatigue, stiffness, anxiety, and depression for TENS with exercise compared with exercise alone. One study found no additional
improvements in FIQ scores when TENS was added to the first three weeks of a 12-week supervised exercise programme.
No serious adverse events were reported in any of the studies although there were reports of TENS causing minor discomfort in a total
of 3 participants.
The quality of evidence was very low. We downgraded the GRADE rating mostly due to a lack of data; therefore, we have little
confidence in the effect estimates where available.
Authors’ conclusions
There was insufficient high-quality evidence to support or refute the use of TENS for fibromyalgia. We found a small number of
inadequately powered studies with incomplete reporting of methodologies and treatment interventions.
P L A I N L A N G U A G E S U M M A R Y
TENS for fibromyalgia in adults
Review question
Does transcutaneous electrical nerve stimulation (TENS) relieve pain in adults with fibromyalgia?
Background
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Fibromyalgia is a long-term medical condition that is characterised by long-lasting widespread pain throughout the body. TENS is
a treatment that involves putting pulsed electrical currents across the surface of the skin using two or four electrodes. It is used to
manage painful conditions. TENS is inexpensive, can be self-administered by people with fibromyalgia, and is not associated with any
particular side effects. TENS reduces pain during movement so it may be useful in addition to other treatments to help people carry
on their normal lives.
Study characteristics
In January 2017, we found eight clinical studies that examined 315 people. We included TENS administered to produce a non-
painful ’tingling’ sensation at the site of pain either as a treatment alone or combined with exercise treatment. All studies used TENS in
comparison with ’fake’ (called placebo or sham) TENS, no treatment, or other treatments such as medicine or hydrotherapy (treatment
in water).
Key results
We did not find enough high-quality studies to allow us to come to any conclusions about the effectiveness of TENS for fibromyalgia
pain. Even though seven studies concluded that TENS relieved pain associated with fibromyalgia, the studies were low quality and the
findings for measures of pain were inconsistently reported. Studies did not measure most of our outcomes and it was not always clear
what aspects of pain were being reported (e.g. present pain, remembered pain, pain severity, etc.). Only one small pilot study found that
one 30-minute treatment of TENS reduced pain on movement during and immediately after treatment; however, there were too few
participants observed and it is unknown whether this effect would be maintained over a longer course of TENS treatments. Overall, it
is not possible to judge whether TENS reduces pain associated with fibromyalgia. There were no serious side events reported in any of
the studies.
Quality of the evidence
We rated the quality of the evidence from studies using four levels: very low, low, moderate, or high. Very low-quality evidence means
that we are very uncertain about the results. High-quality evidence means that we are very confident in the results. The quality of the
evidence was very low overall because of a lack of data.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
TENS compared to placebo TENS for fibromyalgia
Patient or population: adults with f ibromyalgia
Setting: hospital and university clinic
Intervention: TENS
Comparison: placebo TENS
Outcomes Probable outcome with
TENS
Probable outcome with
placebo TENS
Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Participant-
reported pain relief ≥
30% (≥ 30% pain relief )
No data No data Not calculated No data ⊕©©©
Very low
No data
Participant-
reported pain relief ≥
50% (≥ 50% pain relief )
No data No data Not calculated No data ⊕©©©
Very low
No data
PGIC very much im-
proved
No data No data Not calculated No data ⊕©©©
Very low
No data
PGIC much or very
much improved
No data No data Not calculated No data ⊕©©©
Very low
No data
Withdrawals due to ad-
verse events
In a cross-over study,Dailey 2013 reported 2 with-
drawals af ter the no-TENS intervent ion (without
reasons) result ing in missing data f rom the TENS
and placebo TENS intervent ions. Laurett i 2013
reported 2 withdrawals f rom the placebo TENS
group and 1 withdrawal f rom the TENS group due
to absence of symptom relief
Not calculated 54 part icipants per
treatment arm
(2 RCTs)
⊕©©©
Very low
Downgraded by 3 lev-
els due to small number
of studies, part icipants,
and events
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; PGIC: Patient Global Impression of Change; RCT: randomised controlled trial; TENS: t ranscutaneous electrical nerve st imulat ion.
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
This review is based on a template for reviews of drugs used to
relieve fibromyalgia. The aim is for all reviews to use the same
methods, based on new criteria for what constitutes reliable evi-
dence in chronic pain (Moore 2010a; Appendix 1).
Description of the condition
Fibromyalgia is a long-termmedical condition that is characterised
by chronic widespread pain in the muscles and joints, with sen-
sitivity to pressure stimuli. The symptoms may vary from person
to person, but the main symptom is widespread pain throughout
the body. This may be worse in certain areas, such as the back
or neck. Pain may be described as aching, burning, stabbing, or
sharp and may be accompanied by hyperalgesia (heightened sen-
sitivity to pain) and allodynia (pain on very mild stimulus). Pain
is often continuous but it may fluctuate in severity depending on
various factors including stress, physical activity, and the weather.
Exposure to certain environmental stimuli (e.g. smoke, certain
foods, and bright lights) may cause flare-ups. Other presenting
symptoms may include stiffness, especially in the morning; mus-
cle spasm; depression; fatigue; poor sleep quality, including non-
restorative sleep; cognitive difficulties in thinking, learning, atten-
tion, and concentration; headaches, including severe migraines;
and irritable bowel syndrome (Wolfe 2014). Originally, the Amer-
ican College of Rheumatology classification criteria for fibromyal-
gia were widespread pain (axial pain, left- and right-sided pain,
upper and lower segment pain) that lasts for longer than three
months, with pain on palpation at 11 or more of 18 specified ten-
der points (Wolfe 1990). More recently, a definition of fibromyal-
gia has been proposed based on symptom severity and the pres-
ence of widespread pain, which does not require palpation of ten-
der points for diagnosis (Wolfe 2010). Thus, fibromyalgia is di-
agnosed if the person has: a widespread pain index (WPI) of 7
or greater and a symptom severity scale score of 5 or greater, or
a WPI of between 3 and 6 and a symptom severity scale score of
9 or greater; symptoms have persisted at a similar level for three
months or greater; and the pain cannot be explained by another
disorder.
While some rheumatologists have thought of fibromyalgia as a
specific pain disorder, other investigators have characterised it as
a bodily distress syndrome or a physical symptom disorder, or so-
matoform disorder (Wolfe 2014). It is a heterogeneous condition
in which there is abnormal processing of the sensation of pain.
The cause, or causes, are not well understood, but it has features
in common with neuropathic pain, including changes in the cen-
tral nervous system (CNS). Moreover, people with neuropathic
pain and some people with fibromyalgia experience similar sensory
phenomena (Koroschetz 2011). Many people with fibromyalgia
are significantly disabled, and experience moderate or severe pain
for many years. Chronic painful conditions comprised five of the
11 top-ranking conditions for years lived with disability in 2010
(Vos 2012), and are responsible for considerable loss of quality of
life and employment, and increased health costs (Moore 2014a).
Fibromyalgia is common. Numerous studies have investigated
prevalence in different settings and countries. The review by
Queiroz 2013 gave a global mean prevalence of 2.7% (range 0.4%
to 9.3%), and amean in the Americas of 3.1%, in Europe of 2.5%,
and in Asia of 1.7%. Fibromyalgia is more common in women,
with a female to male ratio of 3:1 (4.2%:1.4%). The change in
diagnostic criteria does not appear to have significantly affected
estimates of prevalence (Wolfe 2013). Estimates of prevalence in
specific populations vary greatly, but have been reported to be as
high as 9% in female textile workers in Turkey and 10% in met-
alworkers in Brazil (59% in those with repetitive strain injury;
Queiroz 2013). Risk factors for fibromyalgia include: sex (it is
more common in women than in men); family history (it is more
likely if a relative has the condition); age (it is more common as
age increases); and rheumatic disease (rheumatoid arthritis or lu-
pus) (Wolfe 2013). The financial burden of fibromyalgia on so-
ciety is significant. One cross-sectional study on 299 people with
fibromyalgia in France and Germany estimated that, on average,
people visited their physician 11.6 (France) and 19.6 (Germany)
times per year and missed 32.4 (France) and 25.2 (Germany) days
of work per year (Winklemann 2011). Total annual costs to so-
ciety based on three-month data from 2008 were EUR 7900 in
France and EUR 7256 in Germany per person. Direct costs from
physician clinic visits, medications, and out-of-pocket expenses
were EUR 910 (France) and EUR 1765 (Germany), and indirect
costs from missed days of work and lost productivity were EUR
6990 (France) and EUR 5491 (Germany).
There are no definitive treatments for fibromyalgia. Fibromyalgia
pain is difficult to treat effectively, with only a minority of people
experiencing a clinically relevant benefit from any one interven-
tion. A multidisciplinary approach is now advocated, with phar-
macological interventions being combined with physical or cog-
nitive interventions, or both. Conventional analgesics are usually
not effective. Treatment is often by so-called unconventional anal-
gesics, such as antidepressants such as duloxetine and amitriptyline
(Lunn 2014; Moore 2012a; Sultan 2008), or antiepileptic drugs
such as gabapentin or pregabalin (Moore 2009; Moore 2011a;
Wiffen 2013). The proportion of people who achieve worthwhile
pain relief (typically at least a 50% reduction in pain intensity;
Moore 2013a) is small, generally only 10% to 25%more thanwith
placebo, with numbers needed to treat for an additional beneficial
outcome (NNTB) usually between four and 10 (Wiffen 2013).
People who do experience good levels of pain relief, however, also
benefit from substantial reductions in other symptoms, such as fa-
tigue, function, sleep, depression, anxiety, and ability towork,with
significant improvement in quality of life (Moore 2010b; Moore
2014a; Straube 2011). Fibromyalgia is not particularly different
from other chronic pain in that only a small proportion of study
participants have a good response to treatment (Moore 2013a).
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Description of the intervention
Transcutaneous electrical nerve stimulation (TENS) is the deliv-
ery of pulsed electrical currents across the intact surface of the skin
to stimulate peripheral nerves, principally for pain relief (APTA
2001; Johnson 2014). TENS treatment is usually self-adminis-
tered, ideally following instruction from a healthcare practitioner.
A portable, battery-powered TENS device is used to produce the
electrical currents and these are delivered to the body using self-
adhering electrodes attached to the surface of the skin. TENS
is inexpensive, with a good safety profile compared with medi-
cation. TENS devices and accessories (lead wires and self-adher-
ing electrodes) are available without prescription. In some coun-
tries TENS needs to be prescribed by a healthcare practitioner
to claim reimbursement from social security or health insurance
companies. Professional bodies published robust safety guidelines
to guide judgements about the appropriateness of TENS in cer-
tain situations (Houghton 2010). Contraindications include peo-
ple who have cardiac pacemakers and implantable cardioverter de-
fibrillators. Precautions include pregnancy, epilepsy, active malig-
nancy, deep-vein thrombosis, and frail or damaged skin (Johnson
2011).
TENS devices create pulsed currents with asymmetrical biphasic
rectangular or symmetrical biphasic rectangularwaveforms.TENS
devices are designed so that users can adjust the electrical char-
acteristics of the currents including: pulse frequency (usually less
than 200 Hz), pulse amplitude (usually less than 70 mA), pulse
duration (usually 50 µseconds to 250 µseconds), and pulse pat-
tern (sometimes termed ’mode’ and including continuous, burst,
and modulated). Modulated pulse patterns may help to reduce
tolerance to TENS caused by repeated use and include modulated
frequency, modulated amplitude, and modulated duration (Sluka
2013).
The International Association for the Study of Pain defined two
TENS techniques which are commonly used in the literature
(Charlton 2005): conventional TENS administered using high-
frequency, low-intensity currents to produce a strong non-painful
TENS sensation; and acupuncture-like TENS (AL-TENS) us-
ing low-frequency, high-intensity currents to produce strong non-
painful pulsate sensations, phasic muscle contractions (twitching),
or both (Claydon 2008a). Low-frequency TENS is consistently
defined as the delivery of pulsed current of 10Hz or less or low-fre-
quency trains (bursts) of high-frequency pulsed current (i.e. burst
mode TENS). High-frequency TENS is often described as pulsed
current between about 50 Hz and 100 Hz, although this neglects
frequencies between 11 Hz and 49 Hz and frequencies above 100
Hz. The term medium-frequency TENS is rarely used in the lit-
erature so high-frequency TENS should be used to describe fre-
quencies greater than 10Hz to themaximum setting on the TENS
device, which is usually 150 Hz to 200 Hz (Johnson 2014). High-
frequency TENS is not always applied at a low intensity and low-
frequency TENS is not always applied at a high intensity. Low-
frequency TENS applied 10% below motor threshold generates
analgesia in humans and reduces primary and secondary joint in-
flammation in animal models of nociception (Chen 2008; King
2001; Sluka 1998; Sluka 2013; Vance 2007). The critical factor
for response to TENS is the perceptual experience of the intensity
of currents during stimulation regardless of frequency. Evidence
suggests that optimal hypoalgesia is achieved using pulse ampli-
tudes (mA) that generate a strong, non-painful TENS sensation
and therefore pulse amplitude should be titrated during treatment
to maintain this intensity level (Bjordal 2003; Moran 2011; Sluka
2013). Thus, we intended to undertake a subgroup analysis of
intensity (’strong’ versus ’barely perceptible’), frequency (low fre-
quency versus high frequency when intensity is ’strong’), and tech-
nique (conventional TENS versus AL-TENS), if sufficient data
were available.
Response to TENS is also influenced by site of stimulation ac-
cording to the placement of electrodes. Best practice guidelines
suggest that electrodes should be placed on healthy sensate skin so
that the TENS sensation covers (permeates) the painful area. This
is achieved by placing electrodes directly over or ’bracketing’ the
painful site. This may not always be possible because, for example,
skin sensation is altered, there is a skin lesion, or a body part is
absent. In these circumstances, electrodes are placed over the main
nerves proximal to the site of pain, close to vertebrae of spinal
segments, over contralateral dermatomes, over acupuncture points
(acu-TENS), or over myofascial trigger points. Research findings
on the effect of the site of stimulation on treatment outcome are
ambiguous (Johnson 2014). Consideration also needs to be given
to the duration and regularity of treatment and the timing of out-
come measurements. In particular, evidence suggests that the ef-
fects of TENS are maximal during stimulation or immediately
after stimulation (Sluka 2013), and that some studies have failed
to measure outcome during stimulation (Bennett 2011; Bjordal
2003). Thus, we intended to undertake a subgroup analysis of
during TENS versus after TENS if sufficient data were available.
How the intervention might work
The theoretical underpinning for pain relief by electrical stimula-
tion of the skinwas established through the publication of theGate
Control Theory of Pain by Melzack and Wall (Melzack 1965).
They proposed that neural activity in low-threshold cutaneous
afferents (e.g. A-beta axons) would inhibit onward transmission
of nociceptive (pain-related) information in the spinal cord and
brainstem. Normally, activity in low-threshold cutaneous afferents
is generated by low-intensity mechanical stimuli such as ’rubbing
the skin.’ They suggested that electrical currents could be used
to stimulate the low-threshold cutaneous afferents to reduce pain.
The physiological intention of using conventional TENS is to gen-
erate a strong but non-painful TENS sensation as this is indicative
of selective activation of low-threshold cutaneous afferents (A-beta
axons). Evidence suggests that this inhibits onward transmission
of nociceptive information at the first synapse in the spinal cord or
7Transcutaneous electrical nerve stimulation (TENS) for fibromyalgia in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
brain stem (i.e. segmental modulation; Garrison 1996; Ma 2001).
The intention of using AL-TENS is to generate pulsate sensations
in the skin and underlying tissue or non-painful muscle twitching
(or both) as this produces neural activity in small diameter muscle
afferents leading to activation of descending pain inhibitory path-
ways (DeSantana 2009; Francis 2011; Kalra 2001; Millan 2002).
TENS may also reduce nociceptive input to the CNS by blocking
incoming afferent activity in peripheral neurons, creating a ’busy-
line’ effect (Nardone 1989).
Research on animals suggests that low-frequency TENS, when ad-
ministered just below motor threshold, mediates effects via no-
radrenaline, serotonin, and µ-opioid systems and high-frequency
TENS, when administered just below motor threshold, mediates
effects via noradrenaline, gamma-aminobutyric acid (GABA), and
δ-opioid systems (Kalra 2001; Leonard 2010;Maeda 2007; Santos
2013; Sluka 1999; Sluka 2006; Somers 2009). Whether the fre-
quency-mediated effects of TENS translate into differential hy-
poalgesia in humans when the intensity of TENS is kept con-
stant remains in doubt (Chen 2008; Claydon 2008a). There is ev-
idence that long-term use of opioid medication may impact neg-
atively on response to low-frequency TENS but not on response
to high-frequency TENS (Sluka 2000). Leonard 2011 found that
high-frequency TENS reduced pain in 12 opioid-treated people
with chronic pain and 11 opioid-naïve people with chronic pain,
whereas low-frequency TENS only reduced pain in the non-opi-
oid group. The lack of pain relief during low-frequency TENSwas
attributed to the development of µ-opioid receptor tolerance.
Sham credibility issues in studies of transcutaneous
electrical nerve stimulation
Bennett 2011 examined aspects of fidelity that may contribute to
a risk of bias in TENS studies. Factors that contributed to the
overestimation of TENS effects included inadequate method of
randomisation, small sample sizes, and issues associated with the
implementation of a sham (placebo) control such as allocation
concealment and how blinding was maintained. Various types of
sham control have been used in TENS studies, including deacti-
vated TENS devices that are identical in appearance but deliver
no current and TENS devices that deliver stimulation at the start
of treatment and fade to zero current output over a brief period
of time (e.g. within 45 seconds) (Rakel 2010). There are threats
to the credibility of this approach because active stimulation elic-
its sensations and introduces a risk of bias to sham-controlled in-
terventions. Thus, it is not possible to truly blind the person to
the sensory experience generated by different types of TENS or
the lack of sensation during sham (no current) TENS (or both).
However, the nature of the TENS intervention can be concealed
during pre-study briefing using a process that calibrates the par-
ticipant’s expectations of sensations from study interventions. Par-
ticipants can be briefed that some types of non-invasive electrical
stimulation techniques do not produce sensations during stimu-
lation (i.e. microcurrent therapy) and that they may or may not
experience sensations from the TENS device (Bennett 2011). The
sham (no current) device can look and behave similarly to the in-
tervention device (e.g. identical appearance of the device, flashing
lights, and functioning display panel) and participants can be in-
structed to use the device at a predetermined setting on the dis-
play. Blinding can be monitored by asking participants whether
they believed that “...the device was functioning properly?” (Deyo
1990). Bennett 2011 also examined aspects of fidelity that may
contribute to underestimation of the effects of TENS and found
that the adequacy of the TENS intervention (i.e. the appropriate-
ness of the TENS technique) was the main area of concern. Other
factors contributing to underestimation of the effects of TENS
were: a lack of instruction on how best to administer TENS es-
pecially when self-administering TENS; assessment of adherence;
inadequate reporting of the TENS regimen during use; and failure
to standardise or report concurrent analgesia and to assess com-
parability between groups. We intended to undertake a subgroup
analysis of TENS administered as a sole treatment versus TENS
administered in combination with other treatments if sufficient
data were available.
Why it is important to do this review
TENS is used extensively to manage painful conditions because
it has few contraindications or reported adverse effects and has
no potential for overdose (Johnson 2014). One Cochrane Re-
view by Johnson 2015a concluded that there was tentative evi-
dence that TENS reduces pain intensity when administered as a
stand-alone treatment for acute pain in adults and a non-Cochrane
meta-analysis found superiority of TENS over placebo for reduc-
ing postoperative analgesic consumption (Bjordal 2003). Another
Cochrane Review found only limited evidence of effect for labour
pain (Dowswell 2009). In 2008, one Cochrane Review on TENS
for chronic pain was inconclusive (Nnoaham 2008); although the
2008 review has now been withdrawn, our new review will partly
serve to update it, focusing on fibromyalgia alone. Most Cochrane
Reviews on specific chronic pain conditions have found the ev-
idence to be inconclusive (e.g. osteoarthritis of the knee (Rutjes
2009)) or insufficient to make a judgement (e.g. chronic low back
pain (Khadilkar 2008), cancer pain (Hurlow 2012), and phantom
pain and stump pain (Johnson 2015b)). Non-Cochrane meta-
analyses have found superiority of TENS over placebo for chronic
musculoskeletal pain (Johnson 2007), and osteoarthritis of the
knee (Bjordal 2007). Often systematic reviews and meta-analyses
are hindered by methodological weaknesses including suboptimal
TENS interventions and inadequate study sample sizes (Bennett
2011: Johnson 2010; Sluka 2013). One overview of Cochrane Re-
views of TENS for chronic pain is in development (Catley 2015),
and a new review on TENS for neuropathic pain in adults, which
was developed from Claydon 2010, has been published (Gibson
2017).
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There is evidence that electrode placement site, frequency, and
intensity of stimulation influence TENS outcome although the
precise nature of the interaction is unknown (Chesterton 2003;
Claydon 2008b; Claydon 2013). Studies on healthy people ex-
posed to experimental pain and systematic reviewswithmeta-anal-
yses of people with painful conditions have found that a strong,
non-painful TENS sensation, at or close to the site of pain, pro-
duces optimal analgesic efficacy (Aarskog 2007; Bjordal 2007;
Chen 2011; Claydon 2008a; Moran 2011). Central sensitisation
contributes to pain associated with fibromyalgia and therefore
TENS may be beneficial because it has been shown to reduce this
(Ma 2001).
Exercise is recommended as a treatment for fibromyalgia (
Macfarlane 2017) and evidence suggests that aerobic exercise may
slightly decrease pain intensity (Bidonde 2017), although adher-
ence to exercise programmes may be poor due to pain and fa-
tigue (Bidonde 2014; Busch 2008). As TENS reduces pain during
movement, it may be useful as an adjunct to assist with participa-
tion in exercise and activities of daily living. Some clinical studies
have been published on TENS for managing symptoms associ-
ated with fibromyalgia (Dailey 2013; Lauretti 2013;Mutlu 2013),
and there is a published protocol for a double-blind randomised
clinical study that has yet to be completed (Noehren 2015). Two
large questionnaire surveys on people with fibromyalgia revealed
that 21% of people in the US (Bennett 2007) and 17% of Ger-
mans with fibromyalgia (Häuser 2012) reported use of TENS for
symptom control. To date, only one systematic review exists which
looks at physiotherapy and physical agents used for fibromyal-
gia, of which TENS is included (Winkelmann 2012). Three ran-
domised controlled trials (RCTs) with 82 participants and mean
study duration of five (range three to five) weeks were analysed
but studies were found to be of low methodological quality and
incompletely reported. The authors concluded that TENS was
not an effective treatment option for fibromyalgia. An updated
systematic review of the current evidence of the effects of TENS
for fibromyalgia is needed so that health professionals, researchers,
and people with fibromyalgia can make informed decisions about
its use.
The standards used to assess evidence in chronic pain studies have
changed substantially, with particular attentionbeing paid to study
duration, withdrawals, and statistical imputation following with-
drawal, all of which can substantially alter estimates of efficacy.
The most important change is the move from using mean pain
scores, or mean change in pain scores, to the number of people
who have a large decrease in pain (by at least 50%) and who con-
tinue in treatment, ideally in studies of eight to 12 weeks or longer.
Pain intensity reduction of 50% or more has been shown to cor-
relate with improvements in comorbid symptoms, function, and
quality of life. These standards are set out in the reference guide
for pain studies (PaPaS 2012). This Cochrane Review assessed ev-
idence using methods that make both statistical and clinical sense,
and will use developing criteria for what constitutes reliable evi-
dence in chronic pain (Moore 2010a). The studies included and
analysed needed to meet a minimum of reporting quality (blind-
ing, randomisation), validity (duration, dose and timing, diagno-
sis, outcomes, etc.), and size (ideally at least 500 participants in a
comparison in which the NNTB is four or above; Moore 1998).
This approach sets high standards and marks a departure from
how reviews were conducted previously.
O B J E C T I V E S
To assess the analgesic efficacy and adverse events of TENS alone
or added to usual care (including exercise) compared with placebo
(sham) TENS; no treatment; exercise alone; or other treatment in-
cluding medication, electroacupuncture, warmth therapy, or hy-
drotherapy for fibromyalgia in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included RCTs or quasi-randomised trials of TENS treatment.
We included single treatment interventionswithout follow-up and
gave credence to studies that delivered at least two weeks of treat-
ment and had a study duration of at least eight weeks. We in-
cluded cross-over and parallel-group study designs. We required
full journal publication, with the exception of online clinical study
results summaries of otherwise unpublished clinical studies, and
abstracts with sufficient data for analysis. We did not include short
abstracts (usually meeting reports). We excluded studies that were
non-randomised, studies of experimental pain, case reports, and
clinical observations.
Types of participants
We included studies of adults aged 18 years or above with pain due
to fibromyalgia diagnosed using either the Wolfe (Wolfe 1990;
Wolfe 2010) or earlier criteria in the case of older studies (e.g.
Goldenberg 1987).
Types of interventions
We included studies that evaluated TENS administered using
non-invasive techniques for pain relief. We excluded invasive
techniques such as percutaneous electrical nerve stimulation. We
included TENS administered using a standard TENS device
(Johnson 2014), regardless of the device manufacturer, which de-
livered biphasic or monophasic pulsed electrical currents that were
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greater than 1 mA using at least two surface electrodes. We ex-
cluded TENS delivered using single probe electrodes (i.e. TENS
pens) and studies investigating ’TENS-like’ devices such as neu-
romuscular electrical stimulation (NMES) devices and interferen-
tial current devices. We included studies that administered TENS
at intensities that produced perceptible TENS sensations during
stimulation. To explore suboptimal stimulation, we conducted a
subgroup analysis to compare TENS at intensities described as
’strong’ (optimal) versus those described as ’barely perceptible,’
’faint,’ or ’mild’ (suboptimal). We included TENS administered
on an area of the body that was sensate at either the site of pain or
over nerve bundles proximal (or near) to the site of pain. We in-
cluded AL-TENS delivered at strong intensities to generate mus-
cle twitches. We only included TENS delivered at acupuncture
points if the point was lying over nerve bundles proximal (or near)
to the site of pain. We included any TENS parameters meeting
these criteria; any duration or regularity of TENS treatment; and
either self-applied or therapist-applied TENS treatment. We in-
cluded TENS administered as a sole treatment or in combination
with usual care. We included studies that evaluated TENS versus:
• placebo TENS (e.g. sham (no current) TENS device);
• no treatment or waiting list control;
• usual care (including exercise);
• other treatment.
Sham credibility is an issue in TENS studies (Deyo 1990). We
defined a sham TENS device as a device similar to the one used
in the active group but where the current output was modified so
that there was: no electrical current, a barely perceptible electrical
current, or electrical current that ceased within one minute (Rakel
2010; Sluka 2013). We excluded studies where it was not possible
to isolate the effects of TENS from other treatments.
Types of outcome measures
We anticipated that studies would use a variety of outcome mea-
sures, with the majority of studies using standard subjective scales
(numerical rating scale (NRS) or visual analogue scale (VAS)) for
pain intensity or pain relief, or both. We included measures of
pain at rest and pain on movement. We were particularly inter-
ested in Initiative on Methods, Measurement, and Pain Assess-
ment in Clinical Trials (IMMPACT) definitions for moderate and
substantial benefit in chronic pain studies (Dworkin 2008). These
were defined as:
• at least 30% pain relief over baseline (moderate);
• at least 50% pain relief over baseline (substantial);
• much or very much improved on Patient Global Impression
of Change scale (PGIC; moderate);
• very much improved on PGIC (substantial).
These outcomes concentrate on dichotomous outcomes where
pain responses do not follow a normal (Gaussian) distribution.
People with chronic pain desire high levels of pain relief, ideally
more than 50%, and ideally with no worse thanmild pain (Moore
2013b; O’Brien 2010). We included ’Summary of findings’ ta-
bles as set out in the author guide (PaPaS 2012) where sufficient
data were available. The ’Summary of findings’ table included out-
comes of at least 30% and at least 50% pain intensity reduction,
PGIC, withdrawals due to adverse events, serious adverse events,
and death. We used the GRADE approach to assess the quality
of evidence related to each of the key outcomes listed in Types of
outcome measures (Chapter 12, Higgins 2011), as appropriate.
We planned to extract outcome measurement data before, during,
and after the intervention, where data were available.
Primary outcomes
• Participant-reported pain relief of 30% or greater,
compared with baseline.
• Participant-reported pain relief of 50% or greater,
compared with baseline.
• PGIC much or very much improved.
• PGIC very much improved.
Secondary outcomes
• Any pain-related outcome indicating some improvement
(e.g. outcomes from continuous data such as participant-
reported change in pain intensity reported as mean data. We
intended to make generalised statements if baseline status was
heterogeneous, and large effects in some participants were
masked by small effects in others).
• Any participant-reported change in health-related quality of
life, including activities of daily living and fatigue, using any
validated tool (e.g. 36-item Short Form (SF-36), 6-item Short
Form (SF-6), Euroqol).
• Withdrawals due to lack of efficacy, adverse events, and for
any cause.
• Participants who experienced any adverse event.
• Participants who experienced any serious adverse event.
Serious adverse events typically included any untoward medical
occurrence or effect that at any dose resulted in death, was life-
threatening, required hospitalisation or prolongation of existing
hospitalisation, resulted in persistent or significant disability or
incapacity, was a congenital anomaly or birth defect, was an
’important medical event’ that may have jeopardised the person,
or may have required an intervention to prevent one of the above
characteristics or consequences.
• Specific adverse events, particularly skin reactions,
somnolence, and dizziness.
• Any disability-related or mental health-related outcome.
Search methods for identification of studies
Electronic searches
10Transcutaneous electrical nerve stimulation (TENS) for fibromyalgia in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
We searched the following electronic databases using a combina-
tion of controlled vocabulary (i.e. MeSH and free-text terms) to
identify published articles:
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2016 Issue 12) via CRSO searched on 18 January
2017;
• MEDLINE (via Ovid) from 1950 to 18 January 2017;
• Embase (via Ovid) from 1980 to 18 January 2017;
• CINAHL (via EBSCO) from 1982 to 18 January 2017;
• PsycINFO (via Ovid) from 1806 to 18 January 2017;
• LILACS (via Birme) from 1982 to 18 January 2017;
• PEDRO from 1929 to 18 January 2017;
• Web of Science (SCI, SSCI, CPCI, SCPCI-SSH) to 18
January 2017;
• AMED (via Ovid) from 1985 to 18 January 2017;
• SPORTDiscus (via EBSCO) from 1975 to 18 January
2017.
There were no language restrictions. We tailored the searches
to the individual databases. We adapted the MEDLINE search
strategy for the other databases listed. The search strategy com-
bined the subject-specific search with phase one and two of the
Cochrane Sensitive Search Strategy for RCTs (as published in Sec-
tions 6.3.2.1, 6.3.3.2, and 6.4.11.1 in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011)). The search
strategies can be found in Appendix 2. We identified all relevant
studies irrespective of language and translated articles when pos-
sible.
Searching other resources
We reviewed the bibliographies of RCTs and review arti-
cles, and searched clinical trial databases (e.g. ClinicalTri-
als.gov (www.clinicaltrials.gov), World Health Organization
(WHO) International Clinical Trials Registry Platform (ICTRP,
apps.who.int/trialsearch/), and metaRegister of Controlled Trials
(mRCT, www.isrctn.com/page/mrct) to identify additional pub-
lished or unpublished data. We did not contact investigators or
study sponsors.
Data collection and analysis
Selection of studies
Wedetermined eligibility of studies for inclusion first by title, then
by reading the abstract of each record identified by the search.
We eliminated records where it was clear from the abstract that
they did not satisfy the inclusion criteria, then obtained full copies
of the remaining records. Two review authors (MIJ, CAP) made
the decisions by reading these records independently and reached
agreement by discussion. Disagreements at any stage of the process
were/would have been resolved by consensus using a third review
author as arbiter (GJ).We did not anonymise the records of studies
in any way before assessment. We created a PRISMA flow chart
(Higgins 2011; Liberati 2009).
Data extraction and management
Two review authors (LSC, CAP) extracted data of included studies
independently using a standard form and checked for agreement
before entry into Review Manager 5 (RevMan 2014). Disagree-
ments were resolved by consensus using the arbiter (MIJ). We in-
cluded information about:
• country of origin;
• study design: cross-over, parallel-group;
• study duration;
• study participants: age, gender, fibromyalgia diagnostic
criteria used, duration of pain and symptoms;
• sample size: active and comparator groups;
• concomitant treatments: pharmacological and non-
pharmacological;
• TENS intervention(s) used: type, electrical parameters,
electrode location, perceptual experience during intervention
including intensity of stimulation, dosing regimen;
• comparison group(s) used: placebo, no treatment, usual
treatment, other treatment, dosing regimen;
• outcomes: time points used including follow-up,
withdrawals;
• adverse and serious adverse effects;
• other: sponsorship, country of origin, conflict of interest
statements.
We used these data to populate the Characteristics of included
studies table.
Assessment of risk of bias in included studies
Two review authors (LSC, CAP) independently assessed risk of
bias for each trial, using the criteria outlined in theCochraneHand-
book for Systematic Reviews of Interventions (Higgins 2011), with
disagreements resolved by consensus with a third review author
(MIJ) acing as arbiter. We assessed the following for each trial.
• Random sequence generation (selection bias). We
assessed the method used to generate the allocation sequence as:
low risk of bias (any truly random process, e.g. random number
table; computer random number generator); unclear risk of bias
(method used to generate sequence not clearly stated). We
excluded studies using a non-random process (e.g. odd or even
date of birth; hospital or clinic record number).
• Allocation concealment (selection bias). The method
used to conceal allocation to interventions prior to assignment
determines whether the intervention allocation could have been
foreseen in advance of, or during, recruitment or changed after
assignment. We assessed the methods as: low risk of bias (e.g.
telephone or central randomisation; consecutively numbered,
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sealed, opaque envelopes); unclear risk of bias (method not
clearly stated); high risk of bias (studies that did not conceal
allocation (e.g. open list).
• Blinding of participants and personnel (performance
bias): participants, and care providers administering TENS.
◦ Blinding of participants: low risk of bias (participants
blinded to allocated intervention and unlikely that blinding
broken); unclear risk of bias (insufficient information to permit
judgement of low/high risk of bias); high risk of bias
(participants not blinded to allocated intervention OR
participants blinded to allocated intervention but it was likely
that blinding may have been broken).
◦ Blinding of personnel (care provider(s) administering
TENS): low risk of bias (care provider blinded to allocated
intervention and unlikely that blinding broken); unclear risk of
bias (insufficient information to permit judgement of low/high
risk of bias); high risk of bias (care provider not blinded to
allocated intervention and the two interventions clearly
identifiable to the care provider as experimental and control OR
care provider blinded to allocated intervention but likely that
blinding was broken).
• Blinding of outcome assessment (detection bias):
outcome assessors.
◦ Blinding of assessor: low risk of bias (outcome assessor
(including ’participants’ with respect to self-report outcomes)
blinded to participants’ allocated intervention and unlikely that
blinding broken); unclear risk of bias (insufficient information to
permit judgement of low/high risk of bias); high risk of bias
(outcome assessor (including ’participants’ with respect to self-
report outcomes) unblinded to participants’ allocated
intervention OR outcome assessor blinded to allocated
intervention but likely that blinding was broken)).
• Incomplete outcome data (dropouts). We checked for
possible attrition bias by considering if participant dropout was
acceptable and described: low risk of bias (less than 20% dropout
and appeared to be random with numbers per group provided
along with reasons for dropout); unclear risk of bias (less than
20% and unclear if random with numbers per group and reasons
for dropout not described); high risk of bias (greater than 20%
dropout).
• Incomplete outcome data (protocol violations). We
considered if participants were analysed as per original group
allocation: low risk of bias (if participants were analysed in the
group to which they were originally assigned); unclear risk of
bias (where insufficient information was provided to determine if
analysis was per protocol or intention-to-treat (ITT)); high risk
of bias (where per protocol analysis was used, where available
data were not analysed or participants’ data were included in the
group to which they were not originally assigned).
• Selective reporting. We assessed whether studies selectively
reported outcomes. We assessed the methods as: low risk of bias
(study protocol was available and all prespecified outcomes were
reported or study protocol was not available but all expected
outcomes were reported); unclear risk of bias (inadequate
information to allow judgement of a study to be classified as ’low
risk’ or ’high risk’); high risk of bias (incomplete reporting of
specified outcomes. One or more primary outcomes were
reported using measurements or analysis that were not
prespecified. One or more of the primary outcomes was not
prespecified. One or more outcomes of interest were reported
incompletely and could not be entered into a meta-analysis.
Results for a key outcome expected to be reported were
excluded).
• Size of study (checking for biases confounded by small
size). We assessed this as: low risk of bias (200 participants or
more per treatment arm); unclear risk of bias (50 to 199
participants per treatment arm); high risk of bias (fewer than 50
participants per treatment arm).
• Other sources of bias. We considered other factors such as
whether studies were stopped early, there were differences
between groups at baseline, the timing of outcome measurement,
cointervention comparability, and funding declarations.
Measures of treatment effect
Where available and appropriate we presented quantitative and
ITT data. For dichotomous data (responder analyses), we used
the Initiative on Methods, Measurement and Pain Assessment in
Clinical Trials (IMMPACT) definitions for interpreting the clin-
ical importance in change in outcome measures compared with
baseline (Dworkin 2008).We intended to calculate risk ratio (RR)
and risk difference (RD) with 95% confidence intervals (CI) for
dichotomised outcome measures. We intended to calculate the
NNTB as an absolute measure of treatment effect where possible.
We intended to present pain outcomes collected as continuous
data on identical scales as mean difference (MD) with 95% CI.
We intended to present pain outcomes collected as continuous
data using different scales as standardised mean difference (SMD)
with 95% CI. We intended to interpret reductions in pain over
baseline as follows:
• less than 15%: no important change;
• 15% or greater: minimally important change;
• 30% or greater: moderately important change;
• 50% or greater: substantially important change.
For health-related quality of life data, we intended to consider a
clinical difference greater than 10% of the scale employed to be
minimally important (Furlan 2009).
The IMMPACT thresholds are based on estimates of the degree of
within-person change from baseline that participants might con-
sider to be clinically important. We expected that the studies in
this review would most likely present effect sizes as the mean be-
tween-group change between intervention groups. There is little
consensus or evidence regarding what the threshold should be for
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a clinically important difference in pain intensity based on the be-
tween-groupdifference during or after the intervention. It has been
found that in pharmacological studies, pain outcomes for acute
pain (Moore 2011b; Moore 2011c), back pain (Moore 2010d),
arthritis (Moore 2010c), and fibromyalgia (Straube 2010), tend
to have a U-shaped rather than a bell-shaped distribution, with
some people experiencing a substantial reduction in symptoms,
some minimal to no improvement, and few experiencing mean
(moderate) improvement. Thus, data expressed as means may be
misleading as a small mean between-group effect size may repre-
sent a proportion of participants that actually responded very well
to the intervention (Moore 2013c; Moore 2014a). It is unknown
whether outcomes are commonly bimodally distributed in studies
of TENS. The advantage of focusing on the between-group dif-
ference is that it is the only direct estimate of the mean specific
effect of the intervention and a small mean between-group effect
might accurately represent very small effects of the intervention
for most or all people. We intended to use a threshold of 10 mm
on a 0- to 100-mm VAS for minimally important outcome for
pain when analysing mean between-group change, in line with the
OMERACT 12 group, which states that the proportion of peo-
ple achieving one or more thresholds of improvement from base-
line pain (e.g. greater than 10%, 20% or greater, 30% or greater,
50% or greater) should be reported in addition to mean change
(Busse 2015). We would interpret these findings with caution as
it remains possible that estimates that fall close to this point may
reflect a treatment that benefits an appreciable number of people.
Unit of analysis issues
We intended to split the control treatment arm between active
treatment arms in a single study if the active treatment arms were
not combined for analysis. In the unlikely event that the unit of
randomisation is not the participant, or where a cross-over design
was used, we intended not to include the data unless a suitable
adjustment for the study design had been, or could be, made.
We included cross-over designs but intended only to enter the
first period data into the meta-analysis. If this was not reported,
we intended to note this and not include the data. If data were
reported appropriately, then we intended to include the data using
the generic inverse variance feature.
Dealing with missing data
We intended to use ITT analysis where the ITT population con-
sisted of participants who were randomised, received at least one
dose of the assigned study intervention, and provided at least one
post-baseline assessment. We intended to assign missing partici-
pants zero improvement wherever possible.
Assessment of heterogeneity
We intended to deal with clinical heterogeneity by combining
studies that examined similar conditions. We performed separate
analyses where TENS was compared with different control condi-
tions such as placebo or no treatment control. We intended to ex-
amine heterogeneity using visual inspection of forest plots, the I²
statistic, and L’Abbé Plots (L’Abbé 1987), and the Chi² test, if ap-
propriate.Where significant heterogeneity existed, we intended to
explore subgroup analyses. Preplanned comparisons are described
in the Subgroup analysis and investigation of heterogeneity sec-
tion.
Assessment of reporting biases
The aim of this reviewwas to use dichotomous outcomes of known
utility and of value to patients (Moore 2010b; Moore 2010c;
Moore 2010d; Moore 2013b). It was intended that the review
would not depend onwhat the authors of the original studies chose
to report or not, though clearly difficulties would arise in studies
failing to report any dichotomous results. We planned to extract
and use continuous data, which would probably poorly reflect ef-
ficacy and utility and therefore be useful for illustrative purposes
only. We intended to assess publication bias using a method de-
signed to detect the amount of unpublished data with a null effect
required to make any result clinically irrelevant (usually taken to
mean a NNTB of 10 or higher; Moore 2008). We considered the
possible influence of small-study samples by the risk of bias crite-
rion “study size.” If at least 10 studies were included in a meta-
analysis and included studies differed in sample size, we planned to
visually inspect funnel plots to explore the likelihood of reporting
biases. For studies that used continuous outcomes, we intended
to use Egger’s test to detect small-study bias (Higgins 2011). We
would have interpreted the results of this process cautiously since
we were aware that all approaches to the quantification of possible
reporting biases have important limitations (Moore 2008).
Data synthesis
We intended to perform pooling of results where adequate data
existed using Review Manager 5 (RevMan 2014). We would have
undertaken meta-analyses of outcome data only from suitably ho-
mogeneous studies using a random-effects model.Where possible,
we would have grouped extracted data according to outcome and
measurement time points. Time points would have included dur-
ing stimulation or immediately after stimulation at each treatment
session, or both; and post-intervention follow-up at less than two
weeks’ post-intervention (short-term), two to seven weeks’ post-
intervention (mid-term), and eight weeks or more post-interven-
tion (long-term).
Quality of the evidence
For all analyses, we intended to explicitly and clearly present the
outcome of the ’Risk of bias’ assessments in the reporting. Where
inadequate data were found to support statistical pooling, we
planned to complete a narrative synthesis. Two review authors
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(MIJ, CAP) independently rated the quality of the outcomes. We
used the GRADE (Guyatt 2008) system to rank the quality of the
evidence using the GRADEprofiler Guideline Development Tool
software (GRADEpro GDT 2015), and the guidelines provided
in Chapter 12.2 of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). The GRADE approach uses five
considerations (study limitations, consistency of effect, impreci-
sion, indirectness, and publication bias) to assess the quality of the
body of evidence for each outcome. The GRADE system uses the
following criteria for assigning grade of evidence:
• high: we are very confident that the true effect lies close to
that of the estimate of the effect;
• moderate: we are moderately confident in the effect
estimate; the true effect is likely to be close to the estimate of
effect, but there is a possibility that it is substantially different;
• low: our confidence in the effect estimate is limited; the
true effect may be substantially different from the estimate of the
effect;
• very low: we have very little confidence in the effect
estimate; the true effect is likely to be substantially different from
the estimate of effect.
We decreased the grade rating by one (-1) or two (-2) if we iden-
tified:
• serious (-1) or very serious (-2) limitation to study quality;
• important inconsistency (-1);
• some (-1) or major (-2) uncertainty about directness;
• imprecise or sparse data (-1);
• high probability of reporting bias (-1).
We considered single studies to be both inconsistent and imprecise,
unless the sample size was greater than 400 participants for con-
tinuous data (i.e. more than 200 participants per treatment arm)
and greater than 300 events for dichotomous data. We intended
to present pooled effects for all primary outcomes and associated
GRADE judgements in ’Summary of findings’ tables. In certain
circumstances, the overall rating for a particular outcome was ad-
justed as recommended by GRADE guidelines (Guyatt 2013a).
For example, we considered whether there were so few data that
the results were highly susceptible to the random play of chance,
or if a study used last observation carried forward (LOCF) impu-
tation in circumstances where there were substantial differences in
adverse event withdrawals, one would have no confidence in the
result and would need to downgrade the quality of the evidence
by three levels to very low quality. Also, in circumstances where no
data were reported for an outcome, we reported the level of evi-
dence as very low quality (Guyatt 2013b). In other circumstances,
we would not downgrade for imprecision if CIs were wide, if the
outcome threshold according to how much harm would be ac-
ceptable given a benefit or vice versa.
’Summary of findings’ tables
We included four ’Summary of findings’ tables to present themain
findings in a transparent and simple tabular format. In particular,
we included key information concerning the quality of evidence,
the magnitude of effect of the interventions examined, and the
sum of available data on the outcomes participant-reported pain
relief of 30% or greater, participant-reported pain relief of 50%
or greater, PGIC very much improved, PGIC much or very much
improved, and withdrawals due to adverse events.
Subgroup analysis and investigation of heterogeneity
We anticipated too few data for anymeaningful subgroup analysis.
However, if sufficient data were available, we planned the follow-
ing analyses: where substantial heterogeneity was found (I² greater
than 40%, P < 0.1), we would conduct a subgroup analysis inves-
tigating the possible impact of the TENS technique on analgesic
efficacy. If appropriate, we would have conducted the following
analyses.
• Optimal intensity described as ’strong’ or greater versus
suboptimal intensity described as ’barely perceptible,’ ’faint,’ or
’mild.’
• Low-frequency (10 Hz or less) TENS versus other
frequency (e.g. greater than 10 Hz) TENS.
• Conventional TENS (no visible muscle contraction) versus
AL-TENS (visible phasic muscle contractions).
• Assessment during TENS versus after TENS.
• TENS administered as a sole treatment versus TENS
administered in combination with other treatments.
• TENS administered as a single dose versus repetitive dose.
• Opioid-treated participants versus opioid-naïve
participants.
Sensitivity analysis
Weanticipated too fewdata for anymeaningful sensitivity analysis.
However, if sufficient data were available, we planned to analyse
the effect of excluding studies with high risk of bias and the effect
of using a random-effects versus a fixed-effect model.
R E S U L T S
Description of studies
Results of the search
Searches identified 245 potentially relevant records. After removal
of 61 duplicates, we screened the titles and abstracts of 184 records
and obtained and read the full texts of 19 records (Figure 1). We
included eight studies and found four records that were duplicates
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(Characteristics of included studies table). An abstract by Vance
2015 was categorised as a secondary report of Dailey 2013 be-
cause it presented an analysis of data related to achieving higher-
intensity TENS that was not included in the original study re-
port. We excluded six studies after screening the full text report
(Characteristics of excluded studies table). We identified one on-
going study (Characteristics of ongoing studies table).
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Figure 1. Study flow diagram.
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Included studies
We included eight studies that had 315 adults (299 women) at en-
try (Carbonario 2013; da Silva 2008; Dailey 2013; Di Benedetto
1993; Guo 2005; Lauretti 2013; Lofgren 2009; Mutlu 2013; see
Characteristics of included studies table). The age of participants
was 18 to 75 years in the reports that provided information about
the age range of the sample. There were sevenRCTs and one quasi-
RCT with sequential allocation to groups (Carbonario 2013). Six
studies used a parallel-group design, and two studies used a cross-
over design (Dailey 2013; Lofgren 2009). Study sample sizes were
between 10 and 66 participants and intervention arm size sam-
ples were between five and 43. The period for interventions was
30 minutes (Dailey 2013), seven days (Lauretti 2013), 21 days
(da Silva 2008; Lofgren 2009), 42 days (Di Benedetto 1993),
and 84 days (although the TENS intervention was only for the
first 21 days, Mutlu 2013). The period for interventions used by
Carbonario 2013 was unclear. Assessments of treatment outcome
were taken within the intervention period. Only one study con-
ducted a post-intervention follow-up, which was for 24 months
(Guo 2005).
Six studies used TENS as the sole treatment (da Silva 2008; Dailey
2013; Di Benedetto 1993; Guo 2005; Lauretti 2013; Lofgren
2009), and two studies used TENS in combination with exer-
cise (Carbonario 2013; Mutlu 2013). Five studies used high-fre-
quency TENS (Carbonario 2013; Dailey 2013; Di Benedetto
1993; Lofgren 2009; Mutlu 2013), one study used low-frequency
TENS (da Silva 2008), and two studies used both high and low
frequencies (Guo 2005; Lauretti 2013). Six studies used ’strong’
intensities (Carbonario 2013; Dailey 2013; Guo 2005; Lauretti
2013; Lofgren 2009; Mutlu 2013), one study used ’constant tin-
gling’ (Di Benedetto 1993), and one study used ’pleasant tingling’
(da Silva 2008). Pain was recorded using VAS (Carbonario 2013;
da Silva 2008; Dailey 2013; Lauretti 2013), NRS (Lofgren 2009),
or some other pain scale (Di Benedetto 1993; Guo 2005; Mutlu
2013). The most commonly used health-related quality of life was
the Fibromyalgia Impact Questionnaire (FIQ) (Carbonario 2013;
Lofgren 2009; Mutlu 2013). One study reported outcomes dur-
ing TENS (Dailey 2013), seven studies reported outcomes post-
TENS (Carbonario 2013; da Silva 2008; Di Benedetto 1993; Guo
2005; Lauretti 2013; Lofgren 2009;Mutlu 2013), and two studies
reported outcomes long-term from nine weeks (Mutlu 2013) to
24 months (Guo 2005). We provided a brief description of each
of the included studies below.
Carbonario 2013 conducted a quasi-randomised controlled par-
allel-group study that enrolled 32 women sequentially allocated
to receive an eight-week programme of aerobic and stretching ex-
ercises with or without high-frequency (150 Hz) TENS applied
on bilateral tender points of the trapezium and supraspinatus.
Twenty-eight women completed the study. Exercises with TENS
produced a greater decrease in pain intensity and a greater increase
in pressure pain threshold at tender points than exercises without
TENS.
da Silva 2008 conducted a parallel-group RCT that enrolled 10
people to receive hydrotherapy or TENS at a frequency of 15 Hz.
TENS was administered as three 40-minute sessions per week to a
total of 10 sessions. TENS reduced pain, and improved functional
outcomes and quality of life to a greater extent than hydrotherapy.
Dailey 2013 conducted a double-blinded randomised, placebo-
controlled cross-over study that enrolled 43 women. Each partici-
pant received one 30-minute intervention per week of either active
TENS at 100 Hz, or placebo TENS or no TENS. The order of
interventions was randomised and outcome measures taken whilst
TENS remained switched on. Two participants did not receive
TENS or placebo TENS because of withdrawal from the study.
Active TENS produced higher pressure pain thresholds and lower
pain intensity and fatigue with movement compared with placebo
and no TENS.
Di Benedetto 1993 conducted a parallel-group RCT that enrolled
30 people to a six-week course of either S-adenosyl-L-methionine
(SAMe) or TENS at a frequency of 80 Hz to 100 Hz. There
were decreases in pain, fatigue, and the number of tender points
following SAMe but not during TENS.
Guo 2005 conducted a parallel-group RCT that enrolled 66 peo-
ple to a 20-day course of TENS (dermal neurological electric stim-
ulation), electroacupuncture, or routine medication. TENS was
administered daily using two electrodes applied near to the most
painful site and two electrodes applied to ’supplementary acupunc-
ture points’ at a frequency of 100 Hz for 15 minutes followed by
a frequency of 2 Hz for 15 minutes. Electroacupuncture was ad-
ministered using a G-6805 stimulator and No. 28 filiform needles
inserted ’deeply’ to the same sites as TENS to generate ’deqi.’ Rou-
tine medication was administered using oral doses of oryzanol and
vitamin B1 (30 mg), three times a day and amitriptyline titrated
to 20 mg to 30 mg once per day. TENS and electroacupuncture
reduced pain and recurrence of pain to a greater extent than rou-
tine medication.
Lauretti 2013 conducted a randomised placebo-controlled paral-
lel-group study that enrolled 39 people to one of three interven-
tions: dual-site TENS of the lower back (L5) and the upper back
(C7 and T1); dual-site placebo (no current) TENS of the lower
back (L5) and the upper back (C7 and T1); or single-site TENS of
either the lower back (L5) or upper back (C7 and T1) combined
with single-site placebo (no current) TENS of either the lower
back (L5) and the upper back (C7 and T1). Interventions were
administered for 20 minutes per day for seven consecutive days.
TENS was administered using mixed frequencies of 2 Hz and 100
Hz. For the outcomes associated with pain relief and quality of
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sleep, dual-site TENS was superior to single-site TENS which was
superior to dual-site placebo TENS.
Lofgren 2009 conducted a randomised controlled cross-over study
that enrolled 32 people to self-administer a daily treatment of
superficial warmth (42 °C) using a portable prototype device or
TENS at a frequency of 80 Hz for three weeks with the order
of receiving the treatments randomised. Both treatments reduced
pain compared with baseline but there were no differences in the
amount of pain relief between treatments.
Mutlu 2013 conducted a parallel-group RCT that enrolled 66
people to a 12-week course of supervised exercise with or without
TENS at a frequency of 80 Hz. TENS was administered daily in
the first three weeks of the 12-week course of exercise. Outcomes
for pain, tender point count, FIQ, and SF-36 improved in both
groups. There were superior improvements in outcomes for pain
at week three for participants receiving TENS.
Excluded studies
We excluded six records after screening the full-text report
(Characteristics of excluded studies table).We excluded one record
because we were unable to locate the original source due to an
error in the search citation (Mutlu 2006). We excluded one report
that was a commentary of previously published studies (Simons
2006), one report of a case series (Ido 2003), one report of a study
that was found not to be an RCT (Arroyo 1993), one report of
a study using microcurrent not TENS (Sunshine 1996), and one
report of an RCT where it was not possible to isolate the effects
of TENS from other treatment because TENS was given as com-
bination therapy (Kesiktas 2011).
Ongoing studies
One study was ongoing at the time of this review, for which a
protocol had been published (Noehren 2015). The initial phase
of the study will randomly allocate 360 participants to receive
active TENS, placebo TENS, or standard care (no TENS). See
Characteristics of ongoing studies table.
Risk of bias in included studies
We judged that there was a high risk of bias in seven of the eight
included studies. Our assessment of the risk of bias for the in-
cluded studies is summarised in Figure 2 and Figure 3. We judged
the study by Dailey 2013 to have the lowest risk of bias overall,
although this study still had a risk of bias due to a small sample
size.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
We judged that two studies adequately described the method of
random sequence generation (Dailey 2013; Lauretti 2013) and
one study adequately described allocation concealment (Dailey
2013). We judged one study to have a high risk of selection bias
because participants were allocated consecutively into two treat-
ment groups (Carbonario 2013). We judged the remaining stud-
ies to be at unclear risk of bias because they did not adequately
report the method of random sequence generation and allocation
concealment.
Blinding
Blinding of participants and personnel (performance bias):
participants, and care providers administering TENS
We judged that two studies adequately described the method of
blinding of participants (Dailey 2013; Lauretti 2013) although
Lauretti 2013 used TENS with no current and therefore there is a
challenge to the success of blinding. Therefore, we judged Dailey
2013 as low risk of bias, and Lauretti 2013 as unclear risk of bias
for this domain. We judged five studies to be at high risk of per-
formance bias because there was no attempt to blind participants
or therapists (or both) to treatment groups (Carbonario 2013;
Di Benedetto 1993; Guo 2005; Lofgren 2009; Mutlu 2013). We
judged the remaining study to be at unclear risk of bias.
Blinding of outcome assessment (detection bias): outcome
assessors
We judged that two studies adequately described the method
of blinding of outcome assessment (Dailey 2013; Mutlu 2013).
Dailey 2013 assessed the success of blinding of outcomes asses-
sors to interventions given simultaneously at two body sites. The
success rate of identifying the interventions was 54% and 53%
for active TENS, 50% and 34% for placebo TENS and 58% and
50% for no TENS, with no statistically significant differences be-
tween treatment groups. We judged two studies to be at high risk
of detection bias (Carbonario 2013; Lofgren 2009). We judged
the remaining studies to be at unclear risk of bias.
Incomplete outcome data
We judged three studies to be at low risk of attrition bias because
all participants completed the study with nomissing outcome data
(da Silva 2008; Di Benedetto 1993) or missing outcome data were
balanced across the groups with similar reasons for loss (Mutlu
2013). We judged one study to be at high risk of attrition bias
because there were substantial data missing at six months’, 12
months’, and 24 months’ follow-up (Guo 2005). We judged the
remaining studies to be at unclear risk of attrition bias.
Selective reporting
We judged one study to be at low risk of reporting bias because
there was a protocol registered on ClinicalTrials.gov and analysis
of prespecified outcomes were faithfully reported (Dailey 2013).
We judged one study to be at high risk of reporting bias because
analyses of some outcomes were not prespecified in the methods
section and 100-mmVAS scores were converted into four arbitrary
categories and analysed using frequency counts (Guo 2005). We
judged the remaining studies to be at unclear risk of reporting bias.
Sample size
We judged that there was a high risk of bias due to small sample
sizes with all eight included studies having fewer than 50 partici-
pants per treatment arm.
Other potential sources of bias
We judged that there was a risk of bias from treatment carry-over
effects due to the absence of a washout period for Lofgren 2009.
Potential conflicts of interest or industrial sponsorship (or both)
were not disclosed in the majority of study reports. Dailey 2013
and Lauretti 2013 disclosed that TENS units were donated by a
TENS company. Dailey 2013 disclosed that none of the authors
had conflicts of interest with respect to the study although two
authors had associationswith the company that donated theTENS
devices. Di Benedetto 1993 acknowledged partial study support
by BioResearch, Liscate, Italy.
Effects of interventions
See: Summary of findings for the main comparison TENS
compared to placebo TENS for fibromyalgia; Summary of
findings 2 TENS compared to no treatment for fibromyalgia;
Summary of findings 3TENS with exercise compared to exercise
alone for fibromyalgia; Summary of findings 4 TENS compared
to other active treatment for fibromyalgia
The authors of seven of the eight included studies concluded that
their study provided evidence that TENS was effective at relieving
pain associated with fibromyalgia but the studies had very small
sample sizes and were underpowered. Small studies are known to
be at high risk of producing inaccurate estimates (Moore 1998) and
small-study effects distort the findings of meta-analyses (AlBalawi
2013; Nüesch 2010). Stronger effect estimates in meta-analyses
are found for small-sized studies compared with larger studies
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(Dechartres 2013). Thus estimates of efficacy will only be credi-
ble if data arise from large studies or from pooling multiple mod-
erately sized studies with similar methodology and comparison
groups. The studies in our review did not meet these criteria. We
judged that there were too few data from outcomes that were not
suitably homogeneous for any meaningful statistical pooling of
results. We provide a descriptive narrative of the included studies
for completeness (Table 1).
TENS compared with placebo TENS (e.g. sham (no
current) TENS device)
Two studies included a comparison ofTENSversus placeboTENS
(54 participants in the placebo TENS arm (Dailey 2013; Lauretti
2013). We judged the quality of the evidence using GRADE to
be very low; we downgraded three times due to a lack of data
(Summary of findings for the main comparison).
Primary outcomes
None of the included studies measured primary outcomes as di-
chotomous data (responder analysis).
Participant-reported pain relief of 30% or greater
Neither study measured participant-reported pain relief of 30%
or greater.
Participant-reported pain relief of 50% or greater
Neither study measured participant-reported pain relief of 50%
or greater.
PGIC much or very much improved
Neither study measured PGIC much or very much improved.
PGIC very much improved
Neither study measured PGIC very much improved.
Secondary outcomes
Other pain-related outcomes
Dailey 2013 found that a single 30-minute treatment of TENS re-
duced pain intensity (VAS) on movement compared with placebo
TENS with the mean ± standard error of the mean (SEM) dif-
ference in VAS scores (100 mm) before and during intervention
being 11.1 ± 2.6 mm (95% CI 5.9 to 16.3) for TENS and 2.3
± 2.6 mm (95% CI 2.4 to 7.7) for placebo TENS. There were
no significant differences between TENS and placebo TENS for
pain intensity at rest. This double-blinded randomised, placebo-
controlled cross-over study of 43 participants was described as a
pilot study to inform the design of a larger-scale clinical study.
Dailey 2013 reported that active TENS increased pressure pain
threshold to a greater extent than placebo TENS in the lumbar
region (P < 0.05) but not in the cervical region or anterior tibialis.
Lauretti 2013 reported that mean ± standard deviation (SD) pain
intensity (100-mm VAS) decreased from 85 ± 20 mm at baseline
to 43 ± 20 mm after one week of dual-site TENS (reduction
49.4%) and decreased from 85 ± 10 mm at baseline to 60 ± 10
mm after one week of single-site TENS (pain reduction 29%).
Placebo TENS decreased pain intensity (VAS) from 82 ± 20 mm
at baseline to 80 ± 20 mm after one week (pain reduction 2.5%).
Participant-reported change in health-related quality of life
Dailey 2013 reported that fatigue with movement during the six-
minute walk test was significantly reduced for active TENS com-
pared with placebo TENS (P < 0.05) but not for fatigue at rest.
There were no significant differences between any groups for range
of motion, single leg stance, sit-to-stand test, or six-minute walk
test.
Lauretti 2013 reported that quality of sleep was improved in dual-
site TENS (10 participants) and single-site TENS (eight partic-
ipants) and worsened in the placebo TENS group (four partici-
pants, P < 0.05). ’Quality of fatigue’ was improved in dual-site
TENS (seven participants) and single-site TENS (five partici-
pants) but not in the placebo TENS group (zero participants, P <
0.05). However, as quality of fatigue was not defined, it was un-
clear whether this meant that there was an improvement in level
of fatigue.
Withdrawals
Dailey 2013 reported two withdrawals after the no-TENS inter-
vention (without reasons) resulting inmissingdata from theTENS
and placebo TENS interventions.
Lauretti 2013 reported two withdrawals from the placebo TENS
group and one withdrawal from the TENS group due to absence
of symptom relief.
Adverse events
Lauretti 2013 reported that two participants experienced muscle
soreness following 70 minutes of TENS and six participants expe-
rienced gastric discomfort which they attributed to oral diclofenac
(placebo TENS: four participants; single-site TENS: two partic-
ipants). The authors stated that no adverse events were observed
due to active TENS.
Dailey 2013 did not report adverse events.
Serious adverse events
Neither of the included studies reported any serious adverse events.
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Specific adverse events
Lauretti 2013 reported that two participants experienced muscle
soreness following 70 minutes of TENS.
Disability-related or mental health-related outcome
Neither study reported disability-related or mental health-related
outcomes.
TENS compared with no treatment or waiting list
control
One study included a comparison of TENS against no treat-
ment (Dailey 2013). We judged the quality of the evidence using
GRADE to be very low; we downgraded three times due to a lack
of data (Summary of findings 2).
Primary outcomes
The study did not measure primary outcomes as dichotomous
data (responder analysis).
Participant-reported pain relief of 30% or greater
The study did not report participant-reported pain relief of 30%
or greater.
Participant-reported pain relief of 50% or greater
The study did not report participant-reported pain relief of 50%
or greater.
PGIC much or very much improved
The study did not report PGIC much or very much improved.
PGIC very much improved
The study did not report PGIC very much improved.
Secondary outcomes
Other pain-related outcomes
Dailey 2013 found that a single 30-minute treatment of TENS
reduced pain intensity (VAS) on movement compared with a no-
TENS control with the mean ± standard error of the mean (SEM)
difference in VAS scores (100mm) before and during intervention
being 11.1 ± 2.6 mm (95% CI 5.9 to 16.3) for TENS and 2.6
± 2.5 mm (95% CI 2.8 to 7.5) for no-TENS. There were no
significant differences between TENS and no TENS for pain at
rest. Dailey 2013 reported that active TENS increased pressure
pain threshold to a greater extent than the no-TENS control in
the cervical, lumbar, and anterior tibialis regions (P < 0.05).
Participant-reported change in health-related quality of life
Dailey 2013 reported that fatigue with movement during the six-
minute walk test was significantly reduced for active TENS com-
pared with no TENS (P < 0.001) but not for fatigue at rest. There
were no significant differences between groups for range of mo-
tion, single leg stance, sit-to-stand test, or six-minute walk test.
Withdrawals
Dailey 2013 reported that there were two withdrawals after the
no-TENS intervention (without reasons) resulting in missing data
from the TENS and no TENS interventions.
Adverse events, serious adverse events, specific adverse events
The study did not report adverse events.
Disability-related or mental health-related outcome
The study didnot report disability-related ormental health-related
outcomes.
TENS added to exercise compared with exercise
alone (usual care)
Two studies included a comparison of TENS added to exercise
against exercise alone (49 participants enrolled into each treatment
arm for both studies combined) (Carbonario 2013; Mutlu 2013).
We judged the quality of the evidence using GRADE to be very
low; we downgraded three times due to a lack of data (Summary
of findings 3).
Primary outcomes
Participant-reported pain relief of 30% or greater
Carbonario 2013reported that 30% of 14 participants achieved
pain relief of 30% or greater when TENS was added to an eight-
week programme of aerobic and stretching exercises compared
with 13% of 14 participants in the exercise alone group. These
percentages equate to 4.2 participants in the TENS plus exercise
group and 1.82 participants in the exercise alone group, which
is illogical, and yet the authors did not describe whether they
rounded their figures to the nearest whole number.
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Participant-reported pain relief of 50% or greater
The studies did not report participant-reported pain relief of 50%
or greater.
PGIC much or very much improved
The studies did not report PGIC much or very much improved.
PGIC very much improved
The studies did not report PGIC very much improved.
Secondary outcomes
Other pain-related outcomes
Carbonario 2013reported greater reductions in pain intensity
when TENS was added to an eight-week programme of aerobic
and stretching exercises. The mean ± SD reduction in pain inten-
sity was 20 ± 29 mm for TENS with exercise and 7.0 ± 37 mm
for exercise alone. There were greater increases in pressure pain
threshold at tender points with TENS plus aerobic and stretching
exercises.
Mutlu 2013 reported that three weeks of TENS added to the first
three weeks of a 12-week supervised exercise programme produced
greater than 30% reduction (relative to baseline) in the degree
of tenderness at the tender points (myalgic pain score) measured
using a four-point scale (no pain, mild, moderate, and severe)
at the three and 12 weeks measurement time points. There were
statistically significant improvements in myalgic pain score and
tender point count when TENS was added to exercise compared
with exercise alone.
Participant-reported change in health-related quality of life
Carbonario 2013 reported clinically important improvements in
subscales for work performance, fatigue, stiffness, anxiety, and de-
pression for TENS with exercise compared with exercise alone.
Mutlu 2013 reported that there was no additional improvements
in FIQ scores or SF-36 when TENS was added to a 12-week
supervised exercise programme.
Withdrawals
Carbonario 2013 reported two withdrawals and two dropouts in
equal numbers from each group with no reasons.
Mutlu 2013 reported three withdrawals from each group stating
that there were similar reasons for the withdrawals, although fur-
ther details were not provided. In all instances missing data were
removed from subsequent analysis.
Adverse events, serious adverse events, specific adverse events
Neither study reported adverse events, serious adverse events, or
specific adverse events.
Disability-related or mental health-related outcome
Neither study reported disability-related or mental health-related
outcomes.
TENS compared with other treatment
Four studies included a comparison of TENS versus another treat-
ment: hydrotherapy (da Silva 2008), SAMe (Di Benedetto 1993),
medication (oryzanol and amitriptyline) or electroacupuncture
(Guo 2005), and superficial warmth (Lofgren 2009). We judged
the quality of the evidence usingGRADE to be very low; we down-
graded three times due to a lack of data (Summary of findings 4).
Primary outcomes
Only one study measured primary outcomes as dichotomous data
(responder analysis), but the cut-off point for response was pain
relief of 25% or greater (Lofgren 2009).
Participant-reported pain relief of 30% or greater
Lofgren 2009 reported that 10/28 participants achieved pain re-
lief of 20 units or greater on a 100-unit NRS (i.e. pain relief of
25%) compared with 10/24 participants in the superficial warmth
(42 ºC) group with no statistically significant differences between
groups.
Participant-reported pain relief of 50% or greater
None of the studies reported participant-reported pain relief of
50% or greater.
PGIC much or very much improved
None of the studies reported PGICmuch or verymuch improved.
PGIC very much improved
None of the studies reported PGIC very much improved.
Secondary outcomes
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Other pain-related outcomes
da Silva 2008 reported that TENS reduced pain, and improved
functional outcomes and quality of life to a greater extent than
hydrotherapy but treatment arms only had five participants.
Di Benedetto 1993 reported that SAMe but not TENS reduced
the number of tender points. The total number of tender points
reduced from 10 to five in the SAMe group.
Guo 2005 reported that TENS reduced pain and the recurrence
of pain to more than routine medication (oral oryzanol and vi-
tamin B1 (30 mg three times a day) and amitriptyline (20 mg to
30 mg once per day)). However, it was difficult to interpret the
data analysis because pain was measured using VAS but then re-
categorised into discrete groups (’no effect,’ ’effect,’ ’remarkable
effect,’ and ’curing pain’). At 24-month follow-up after treatment,
the number of participants that the authors described as “cured”
or “having significant effects” were 1/14 for TENS, 1/13 for elec-
troacupuncture, and 1/2 for medication.
Lofgren 2009 did not report other pain-related outcomes.
Participant-reported change in health-related quality of life
Di Benedetto 1993 reported that SAMe but not TENS reduced
fatigue.
Lofgren 2009 reported improvements in subscales for physical
function, number of days felt good after superficial warmth ther-
apy but not TENS, with a strong tendency of the score for depres-
sion to increase (worsen) after TENS.
da Silva 2008 and Guo 2005 did not report participant-reported
change in health-related quality of life.
Withdrawals
Guo 2005 reported missing data for 22 participants at six months’
follow-up, 29 participants at 12 months’ follow-up, and 37 par-
ticipants at 24 months’ follow-up, although there were no missing
data at 45 days’ follow-up.
Lofgren 2009 reported two withdrawals for reasons “unrelated
to treatment.” In addition, one participant did not complete the
TENS intervention and two participants did not complete the
warmth intervention. An ITT and a per-protocol analysis was
conducted although how dropout data were handled was unclear.
da Silva 2008 and Di Benedetto 1993 did not report withdrawals.
Adverse events, serious adverse events, specific adverse events
Lofgren 2009 reported two adverse events: two participants re-
ported increased pain during TENS.
da Silva 2008, Di Benedetto 1993, and Guo 2005 did not report
adverse events, serious adverse events, or specific adverse events,
Disability-related or mental health-related outcome
Di Benedetto 1993 reported that TENS produced a reduction in
Hamilton Rating Scale for Anxiety score only at the end of treat-
ment whereas SAMe produced reductions in scores for both the
Hamilton Rating Scale for Depression and the Hamilton Rating
Scale for Anxiety by day 14 of treatment.
da Silva 2008, Guo 2005, and Lofgren 2009 did not report dis-
ability-related or mental health-related outcomes.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
TENS compared to no treatment for fibromyalgia
Patient or population: adults with f ibromyalgia
Setting: university clinic
Intervention: TENS
Comparison: no treatment
Outcomes Probably outcome with
TENS
Probable outcome with
no treatment
Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Participant-
reported pain relief ≥
30% (≥ 30% pain relief )
No data No data Not calculated No data ⊕©©©
Very low
No data
Participant-
reported pain relief ≥
50% (≥ 50% pain relief )
No data No data Not calculated No data ⊕©©©
Very low
No data
PGIC much or very
much improved
No data No data Not calculated No data ⊕©©©
Very low
No data
PGIC very much im-
proved
No data No data Not calculated No data ⊕©©©
Very low
No data
Withdrawals due to ad-
verse events
In a cross-over study, Dailey 2013 reported that
there were 2 withdrawals af ter the no-TENS in-
tervent ion (without reasons) result ing in missing
data f rom the TENS and placebo TENS interven-
t ions
Not calculated No data ⊕©©©
Very low
Downgraded by 3 lev-
els due to small number
of studies, part icipants,
and events
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; PGIC: Patient Global Impression of Change; RCT: randomised controlled trial; TENS: t ranscutaneous electrical nerve st imulat ion.
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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TENS with exercise compared to exercise alone for fibromyalgia
Patient or population: adults with f ibromyalgia
Setting: hospital and university clinic
Intervention: TENS with exercise
Comparison: exercise on its own
Outcomes Probably outcome with
TENS with exercise
Probable outcome with
exercise on its own
Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Participant-
reported pain relief ≥
30% (≥ 30% pain relief )
Carbonario 2013 reported that 30% of 14 part ici-
pants in the TENS with exercise group achieved
≥ 30% reduct ion in pain and this was signif i-
cant ly greater than 13% of 14 part icipants in the
exercise without TENS group. However, these
percentages equate to 4.2 part icipants and 1.82
part icipants respect ively, which is illogical. The
mean ± SD reduct ion in pain intensity was 20 ± 29
mm for TENS and 7.0 ± 3 7 mm for the exercise
without TENS
Not calculated 28
(1 RCT)
⊕©©©
Very low
Downgraded by 3 lev-
els due to small number
of studies, part icipants,
and events
Participant-
reported pain relief ≥
50% (≥ 50% pain relief )
No data No data Not calculated No data ⊕©©©
Very lowLOW
No data
PGIC much or very
much improved
No data No data Not calculated No data ⊕©©©
Very low
No data
PGIC very much im-
proved
No data No data Not calculated No data ⊕©©©
Very low
No data
Withdrawals due to ad-
verse events
Carbonario 2013 reported 2 withdrawals and 2
dropouts in equal numbers f rom each group with
no reasons. Mutlu 2013 reported 3 withdrawals
f rom the exercise alone group and 3 withdrawals
f rom the exercise with TENS groups stat ing that
Not calculated No data ⊕©©©
Very low
Downgraded by 3 lev-
els due to small number
of studies, part icipants,
and events
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there were sim ilar reasons for the withdrawals,
although further details were not provided
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval;PGIC: Patient Global Impression of Change;RCT: randomised controlled trial;SD: standard deviat ion; TENS: t ranscutaneous electrical nerve st imulat ion.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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TENS compared to another treatment for fibromyalgia
Patient or population: adults with f ibromyalgia
Setting: hospital
Intervention: TENS
Comparison: another treatment (e.g. superf icial warmth, hydrotherapy, electroacupuncture, medicat ion)
Outcomes Probably outcome with
TENS
Probably outcome with
another treatment
Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Participant-
reported pain relief ≥
30% (≥ 30% pain relief )
Lofgren 2009 reported that post-TENS 10/ 28
part icipants analysed achieved a decrease in
pain severity of ≥ 20 units on a 100-unit NRS
(i.e. pain relief of 25%) compared with 10/ 24
part icipants in the superf icial warmth (42 °C)
group with no stat ist ically signif icant dif f erences
between the groups
Not calculated No data ⊕©©©
Very low
Downgraded by 3 lev-
els due to small number
of studies, part icipants,
and events
Participant-
reported pain relief ≥
50% (≥ 50% pain relief )
No data No data Not calculated No data ⊕©©©
Very low
No data
PGIC much or very
much improved
No data No data Not calculated No data ⊕©©©
Very low
No data
PGIC very much im-
proved
No data No data Not calculated No data ⊕©©©
Very low
No data
Withdrawals due to ad-
verse events
Lofgren 2009 reported that 2 part icipants re-
ported increased pain during TENS
Not calculated No data ⊕©©©
Very low
Downgraded by 3 lev-
els due to small number
of studies, part icipants,
and events
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; NRS: numerical rat ing scale; PGIC: Patient Global Impression of Change; TENS: t ranscutaneous electrical nerve st imulat ion.
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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D I S C U S S I O N
Summary of main results
The objective of this review was to assess the analgesic efficacy and
adverse events of TENS for fibromyalgia in adults. We included
sevenRCTs and one quasi-RCTwith 315 adults (299women) and
treatment sample sizes between five and 43. No studies measured
participant-reported pain relief of 30% or greater as a dichoto-
mous outcome and no studies measured PGIC, both set as pri-
mary outcomes in our review. Seven studies concluded that TENS
was effective at relieving pain associated with fibromyalgia but we
have very little confidence in these conclusions because sample
sizes were too small. There were too few data, and outcomes were
not suitably homogeneous, for any meaningful statistical pooling
of results. Small studies are known to be at high risk of producing
inaccurate estimates (Moore 1998) and small-study effects distort
the findings of meta-analyses (AlBalawi 2013;Nüesch 2010), with
stronger effect estimates in meta-analyses for small-sized studies
compared with larger studies (Dechartres 2013). Estimates of ef-
ficacy are only credible when data arise from large studies or from
pooling multiple moderately sized studies with similar method-
ology and comparison groups. The studies in our review did not
meet these criteria. Thus, the quality of the evidence was very low
when assessed using GRADE. The study with the lowest risk of
bias overall was a double-blind randomised, placebo-controlled
cross-over pilot study of 43 participants that found that a single
30-minute treatment of TENS reduced movement-related pain
intensity and fatigue and increased pressure pain thresholds com-
pared with placeboTENS (Dailey 2013). There were no reports of
participants experiencing any serious adverse events duringTENS,
although in our experience, adverse events are generally poorly
reported. Four specific adverse events were recorded: two partici-
pants experienced muscle soreness following 70 minutes of TENS
(Lauretti 2013) and two participants reported increased pain dur-
ing TENS (Mutlu 2013).
Overall completeness and applicability of
evidence
There was insufficient robust evidence to support or refute the use
of TENS for fibromyalgia. At face value, the methodology used in
the studies appeared robust but on closer inspection study reports
lacked clarity and detail. Replication of most studies would be
impossible. Many study reports lacked fundamental information
about pain outcomes such as whether scores were for: pain sever-
ity or some other aspect (e.g. bothersomeness); retrospective pain
(over what duration) or present pain; pain at rest or on movement;
generalised pain or localised pain; mean pain or worst pain. The
precise instructions given to participants about how to rate pain
severity were rarely reported. The timings of pain measurement
varied across studies and sometimes it was not possible to ascer-
tain whether pain outcomes were measured during or after TENS.
This is crucial because studies suggest that maximum pain relief is
obtained while TENS is switched on (i.e. during TENS; Johnson
2014).
There is a decline in the number of people that use TENS over
time Johnson 2014 though a small proportion of people con-
tinue to use TENS for chronic pain for many years Bates 1980;
Johnson 1992. For this reason, short-term studies on fibromyal-
gia, such as those included in this Cochrane Review, are of lim-
ited value when assessing TENS for chronic pain. More studies
are needed to address issues such as frequency and duration of
TENS treatment as a long-term intervention. Evidence from one
Cochrane Review of 19 short-term studies provided tentative ev-
idence that TENS as a stand-alone treatment reduces pain inten-
sity over and above that seen with placebo (no current) for acute
pain in adults, although small sample sizes prevented definitive
conclusions (Johnson 2015a).
There was variation in the design of TENS treatments across stud-
ies and reports lacked specific details of the parameters and tech-
niques used for TENS. Blinding is a challenge in TENS studies
because participants experience a TENS sensation during treat-
ment. The study by Dailey 2013 included in this review was an
exemplar of good practice when designing, operationalising, and
assessing blinding in TENS studies. They used an authentic sham
TENS device that delivered a current for a short period of time
before declining to zero current output. They also monitored the
success of blinding post-intervention.
Quality of the evidence
The quality of the evidence was very low when assessed using
GRADE, due to a lack of data. There were fewer than 400 partic-
ipants for continuous data and 300 events for dichotomous data,
and more than 25% of participants were included in studies with
unclear or high risk of bias. There was a high risk of bias due to
inadequate sample size and for blinding. There was no single study
with low risk of bias for all items.
Potential biases in the review process
Review authors were not blinded from authors’ names, institu-
tions, and journal name or study results at any stage of the review
process. Pairs of review authors undertook each stage of the review
process independently, including robust searches of databases and
a wide variety of sources, and we compared the outcomes.
Agreements and disagreements with other
studies or reviews
31Transcutaneous electrical nerve stimulation (TENS) for fibromyalgia in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cochrane Reviews on TENS for specific types of pain have been
inconclusive due to insufficient evidence for phantom and stump
pain in adults (Johnson 2015b), and cancer pain in adults (Hurlow
2012). Superiority of TENS over placebo has been reported by
non-Cochrane meta-analyses for chronic musculoskeletal pain
(Johnson 2007), and osteoarthritis of the knee (Bjordal 2007).
One Cochrane protocol for an overview of Cochrane Reviews for
TENS for chronic pain has been published (Catley 2015), and
there are published protocols for TENS for chronic neck pain
(Porfírio 2015) and TENS for neuropathic pain in adults (Gibson
2017). One Cochrane Review on TENS of 19 RCTs (1346 par-
ticipants) provides tentative evidence that TENS as a stand-alone
treatment reduces pain intensity for acute pain in adults, although
there was a high risk of bias associated with inadequate sample
sizes thatmade definitive conclusions impossible (Johnson 2015a).
The systematic review and guideline for fibromyalgia published
by Winkelmann 2012 did not recommend TENS as a treatment
for fibromyalgia pain due to low-quality evidence and the updated
German guidelines for fibromyalgia gave a negative recommenda-
tion for TENS (Winkelmann 2017).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
For people with fibromyalgia
There is no high-quality evidence to support or refute the use of
transcutaneous electrical nerve stimulation (TENS for fibromyal-
gia. Further high-quality research is needed before conclusions can
be made about the efficacy and safety of TENS.
For clinicians
Whether TENS should be considered as a potential treatment
option for fibromyalgia remains a matter for debate. At present,
there is insufficient evidence to support or refute the use of TENS
for fibromyalgia.
For policy-makers
Our analysis of seven randomised controlled trials (RCTs) and one
quasi-RCT with 315 adults found insufficient evidence to support
or refute the use of TENS for fibromyalgia. Studies had a high
risk of bias associated with inadequate sample sizes in treatment
arms and there was variability in study methodology and TENS
dosage.
For funders
The safety profile and ease of use of TENS compares favourably
to alternative treatments because it can be self-administered and
is inexpensive and readily available without prescription. In some
countries, TENS needs to be prescribed by a healthcare practi-
tioner to claim reimbursement from social security or health in-
surance companies.
Implications for research
General
This review has identified the need for high-quality research with
long-term follow-up investigating the use of TENS for fibromyal-
gia pain. All the studies included in this review had design lim-
itations such as inadequate sample sizes, outcome measures, and
follow-up.
Design
As with previous Cochrane Reviews on TENS, we found a small
number of inadequately powered studies with incomplete report-
ing of methodologies and treatment interventions. The CON-
SORT statement for non-pharmacological treatments should be
adopted to report all aspects of study design and subsequent report-
ing (Boutron 2008). A comprehensive review of TENS method-
ologies by Bennett 2011 provides detailed criteria and operational
guidelines to aid the design of future RCTs on TENS. Pain, Pallia-
tive and Supportive Care (PaPaS) guidance suggests that a sample
size of 200 participants per treatment arm is necessary for a low
risk of bias in RCTs so much larger sample sizes per treatment
arms are needed in the future. The study by Dailey 2013 included
in this review has been used to inform the design of a phase II
randomised, double-blind, placebo-controlled, multicentre clini-
cal study that plans to recruit 360 participants with fibromyalgia
and a protocol for this study has been published (Noehren 2015).
It is expected that the findings will be available in a future update of
this review. For meta-analyses, the PaPaS template protocol for the
evaluation of drugs for neuropathic pain recommends that at least
500 participants would be needed to measure the magnitude of a
treatment effect adequately for comparisons in which the number
needed to treat for an additional beneficial outcome (NNTB) is
four or above (Moore 1998).
To assess the effects of TENS on chronic pain long-term studies
of a minimum of six weeks, but ideally more than six months,
are necessary to monitor the decline in people who continue to
use TENS long term. Ideally, TENS should be self-administered
at home with people using TENS regularly throughout the day
whenever they are in pain and for at least 30 minutes at a time
whenever possible. In such studies, barriers to effective long-term
TENS use should be evaluated and resolved before the start of
the TENS intervention. Gladwell 2015a suggested that a learning
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phase should be incorporated into future studies to allow people
to maximise the complex pattern of TENS usage. This could be
achieved during a ’run-in’ period in an enriched enrolment ran-
domised withdrawal design whereby all participants initially re-
ceive active TENS to titrate dosage and optimise TENS technique
(Moore 2013c). Participants who do not achieve benefits or ex-
perience adverse events (or both) are withdrawn from the study
and the remaining participants randomised to receive active or
placebo TENS to determine efficacy. Blinding of participants to
active and placebo TENS becomes a challenge in such a design be-
cause participants become aware of sensations generated by TENS
in the run-in phase. However, electrotherapeutic devices that do
not produce sensations during stimulation are available (e.g. mi-
crocurrent) and information about them can be used in briefing
information to create uncertainty about the need for TENS sen-
sation for beneficial effects (see Johnson 2014, p. 170) This, cou-
pled with the use of credible sham (no current) TENS devices,
can effectively blind participants (Rakel 2010). Blinding can be
monitored post-intervention using simple questions such as ’do
you believe your TENS device was functioning properly?’ (Deyo
1990). Monitoring TENS usage in home studies can be achieved
using electronic monitoring devices to assure participant compli-
ance with the recommendedTENS treatment protocol and TENS
usage can also be used as an outcome measure (Pallett 2014).
To ensure high-quality evidence in future studies - in addition
to having an adequate sample size, adequate dose, and a credible
sham device - researchers should consider measuring pain both
during use of TENS and afterwards and also monitoring ongoing
use of TENS. A health economic assessment would also be useful
to enable a cost-benefit analysis to be produced.
Measurement
Future studies should use pain outcomes recommended by IMM-
PACT. The primary outcome should be the number of partici-
pants reporting at least a 30% or 50% reduction in pain inten-
sity while TENS is switched on. Concurrent analgesia should be
standardised and monitored. However, evaluating TENS using a
unidimensional pain scale is likely to overlook other potential ben-
efits such as ’distraction from pain,’ alleviation of other unpleasant
sensations (e.g. muscle tension or spasm), reduction inmedication
consumption, and improvements in function (Gladwell 2015b).
These should be considered important secondary outcomes.
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groups
Condition and number of participants randomised: fibromyalgia (1990 American Col-
lege of Rheumatology) 32 allocated to groups
Groups: TENS (n = 16), exercise alone (n = 16).
Participants Demographics: n = 32, mean age 53 years, all women.
Setting: Unit of Rehabilitation of Physical Therapy, General Hospital Pirajussara, Brazil
Inclusion: aged ≥ 18 years, referred to physiotherapy.
Exclusion: use of pacemaker, heart disease, other forms of chronic pain, seizures, preg-
nancy, or arthritis
Withdrawal/dropouts: 4 (2 in each group).
Interventions Where applied: Unit of Rehabilitation of Physical Therapy,GeneralHospital Pirajussara,
Brazil
Applied by: physiotherapist.
Instructions to participants: instructed how to carry weights and were given an exercise
programme. Instructions about use of TENS not reported
Duration of intervention: unclear.
TENS (with exercise)
Waveform: continuous.
Frequency: 150 Hz.
Pulse duration: 150 µs.
Pulse amplitude/intensity: strong sensation without muscle contraction
Electrodes: dimensions not reported.
Electrode placement: over bilateral tender points of trapezium and supraspinatus
Duration and frequency of Rx: 30 minutes, unclear frequency.
Device and manufacturer: Physiotonus III TENS, BIOSET, Brazil
Exercise (alone)
All groups received programme of 11 stretches and aerobic exercise at own speed for 30
minutes. Completed for 8 weeks
Outcomes Duration of follow-up: during intervention period only - number of days unclear. No
post-intervention follow-up
Outcomes: pain (VAS, PPT), Fibromyalgia Impact Questionnaire
Type of analysis: per-protocol, n = 14 per group.
Statistical analysis: within-group and between-group analyses (t test andMannWhitney)
Adverse effects: not reported.
Notes Country of origin: Brazil.
Conflict of interest: not reported.
Sponsorship: not reported.
Risk of bias
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Carbonario 2013 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Reported as sequential allocation.
Allocation concealment (selection bias) High risk Participants consecutively allocated to each
group.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants: not blind.
Care providers administering TENS: not
blind.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessors: not blind.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawals (n = 2) and dropouts (n = 2)
reported but no reasons provided.
An equal number of participants withdrew
from each group but no information in-
cluded as to how the data were dealt with
Selective reporting (reporting bias) Unclear risk No protocol registered or published. Pre-
specified primary outcomes for pain were
reported
Sample size High risk < 50 participants per treatment arm.
Other bias Unclear risk Conflict of interest: not reported.
Sponsorship: not reported.
Study stopped early: no.
Parity of groups at baseline: yes - no sig-
nificant differences in medication, exacer-
bating features, duration of disease, pain
severity, Fibromyalgia Impact Question-
naire, pain thresholds, tender point index
Timing of outcome measurement between
groups: identical.
Comparability of cointerventions between
groups: not reported
Funding declarations: not reported.
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da Silva 2008
Methods Type of study: randomised, controlled, parallel group.
Condition and number of participants randomised: fibromyalgia (1990 American Col-
lege of Rheumatology Criteria) 10 randomised
Groups: TENS group (n = 5), hydrotherapy group (n = 5).
Participants Demographics: n = 10, mean age 48.8 years, 9 women.
Setting: Unicapital, São Paulo, Brazil.
Inclusion: diagnosis of fibromyalgia according to the AmericanCollege of Rheumatology
criteria
Exclusion: neurological disease, cardiovascular disease, pacemakers, pregnant, skin dis-
orders
Withdrawal/dropouts: none.
Interventions Where applied: Physiotherapy Clinic of the Unicapital.
Applied by: not reported.
Instructions to participants: not reported.
Duration of intervention: 3 weeks.
TENS
Waveform: not reported.
Frequency: 15 Hz.
Pulse duration: 150 µs.
Pulse amplitude/intensity: constant tingling throughout the application time
Electrodes: electrodes of surface and conductive water-based gel
Electrode placement: bilaterally to tender points of trapezium, supraspinatus, gluts mus-
cles, and knee medial joint line
Duration and frequency of Rx: 3 sessions per week, 40 minutes each session, total of 10
sessions
Device and manufacturer: Quark (Brazil).
Hydrotherapy
Exerciseswithin pool. 5minutes ofwarm-up (walkingpool length and activemobilisation
with flexion and extension of cervical spine, shoulder, hips, knees, and ankle); followed
by20minutes of muscle stretch (3 × 20 s at each of the following locations neck, shoulder,
elbow and hand, hip, knee); followed by 15 minutes of aerobic exercise by walking with
movements of upper and lower limbs
Duration and frequency of Rx: 10 sessions, 40 minutes each session, for 3 weeks
Pool temperature: unknown.
Outcomes Duration of follow-up: during intervention period only (3 weeks). No post-intervention
follow-up
Outcome: at baseline and post-intervention; flexibility fingertip to floor test, VAS, SF-36,
Nottingham Health Profile, Beck Depression Inventory
Type of analysis: per-protocol.
Statistical analysis: pre - post intervention (t test or Mann-Whitney). No comparison
between interventions
Adverse effects: not reported.
Notes Country of origin: Brazil.
Conflict of interest: not reported.
Sponsorship: not reported.
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da Silva 2008 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study reported as randomised but method
not described.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants: not reported.
Care providers administering TENS: not
reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors: not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed study and there
were no missing outcome data
Selective reporting (reporting bias) Unclear risk No protocol registered or published. Pre-
specified primary outcomes for pain re-
ported
Sample size High risk < 50 participants per treatment arm.
Other bias Unclear risk Conflict of interest: not reported.
Sponsorship: not reported.
Study stopped early: no.
Parity of groups at baseline: no significant
differences for any outcome measures
Timing of outcome measurement between
groups: identical.
Comparability of cointerventions between
groups: not reported
Funding declarations: not reported.
Dailey 2013
Methods Type of study: randomised, controlled, cross-over.
Condition and number of participants randomised: fibromyalgia (1990 American Col-
lege of Rheumatology Criteria) 43 randomised
Groups: active TENS (n = 41 analysed), placebo TENS (n = 41 analysed), no-TENS (n
= 43 analysed)
Participants Demographics: n = 43, mean age 49.2 years, 42 women.
Setting: University of Iowa, IA, USA.
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Dailey 2013 (Continued)
Inclusion: diagnosis of fibromyalgia by a physician; history of cervical or lumbar pain;
stable pharmaceutical management for 1 month prior to starting the study
Exclusion: used TENS in past 5 years, active inflammatory condition, pacemaker, preg-
nant, uncontrolled hypertension, significant cognitive deficits
Withdrawal/dropouts: 2 in active TENS group, 2 in placebo TENS group, 0 in no-
TENS group
Interventions Where applied: University Rheumatology Clinic.
Applied by: TENS assessor (unblinded). Cloth over stimulation area and TENS unit
covered for all conditions
Instructions to participants: ”You will receive one of three treatments: strong sensation
TENS, no-sensation TENS or no TENS. The strong-sensation TENS will feel like a
twitching or tapping. The no-sensation TENS will be subtle, and you many not feel
anything at all. The no TENS treatment means that a TENS unit will be attached to the
electrodes but not turned on. Neither you nor the outcomes assessor will know which
study treatment you are receiving.“
Duration of intervention: single treatment of 30 minutes.
TENS (strong sensation TENS)
Waveform: not reported.
Frequency: 100 Hz.
Pulse duration: 200 µs.
Pulse amplitude/intensity: maximal tolerable intensity (mean ± SD: 39.93 ± 13.79 mA)
. Adjustments made to pulse amplitude at 5-minute intervals to maintain the strong
sensation of TENS
Electrodes: butterfly-shaped electrode (Stimcare PremiumElectrode; Empi, St Paul,MN,
USA) dimensions not reported
Electrode placement: participant preference for 1 of 2 locations cervical-thoracic junction
(n = 19) or lumbo-sacral junction (n = 24)
Duration and frequency of Rx: once a week over 3-week period, with treatment duration
of 30 minutes. Washout period of 1 week between groups/conditions
Device/manufacturer: Rehabilicare Maxima TENS units (Empi).
Placebo TENS (no-sensation TENS)
Sham TENS device used to deliver TENS at 100 Hz, 200 µs for 30 s after which the
current amplitude was programmed to decrease (fade away) to 0 mA over 15-s
No-TENS
Electrodes attached to participant’s skin but TENS device not switched on
Outcomes Duration of follow-up: during intervention only; 30 minutes. No post-intervention
follow-up
Outcomes: at baseline: VAS (fatigue at rest, pain at rest), 6-minute walk test (VAS fatigue
with movement and pain with movement), range of motion, sit-to-stand, single leg
stance, pressure pain threshold. During TENS at 30 minutes: VAS (fatigue and pain at
rest) pressure pain threshold, 6-minute walk test (VAS fatigue and pain with movement)
, range of motion, sit-to-stand, single leg stance, conditioned pain modulation. Pressure
pain threshold taken at pain site and tibialis anterior, perceived effectiveness (10-cm VAS
”how effective was your treatment today?“)
Blinding of the outcome assessor: ”What Rx did the subject receive today - active TENS,
placebo TENS, control TENS?“
Type of analysis: per protocol with n = 41 for active and placebo TENS and n = 43 for
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Dailey 2013 (Continued)
no-TENS group
Statistical analysis: descriptive statistics with 95% confidence intervals. Chi² tests used to
make comparisons of categorical variables. Mixed model approach used for comparison
between TENS treatment groups which accounts for the repeated measures collected
through the cross-over design. To reduce the chance of a type 1 error in multiple com-
parisons, Tukey adjusted P values were used
Adverse effects: not reported.
Notes Country of origin: USA.
Conflict of interest: 2 authors had support from DJO (Vista, CA, USA)
Sponsorship: grant from American Physical Therapy Association and University of Iowa.
TENS units donated by company
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using sequentially numbered
opaque sealed envelopes which were not
available to the outcomes assessor
Allocation concealment (selection bias) Low risk Order of TENS treatment randomised by
drawing the order out of a hat and was only
available to person allocating participants
to groups
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants: blind to active and placebo
TENS but not to no-TENS interventions.
”The subject was blinded to the active
TENS and placebo TENS treatments.“
Placebo TENS administered using a de-
vice that gradually reduced current ampli-
tude to 0mA over a 30-second period. This
has been shown to be a viable method of
creating the impression of receiving active
TENS (Rakel 2010). Participants would
have been aware that they were allocated to
the no-TENS intervention
Care providers administering TENS: not
blind. The ”TENS assessor“ provided in-
structions to the participant about how to
apply TENS
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors: blind. ”The outcomes
assessors remainedblinded to all three treat-
ments. “The no-TENS control was com-
pleted with the TENS unit turned off so as
to blind the outcome assessor.”
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawals and dropouts reported but no
reasons provided. Equal numbers of with-
drawals from TENS and placebo TENS (n
= 2), no withdrawals from the no-TENS
intervention. Data excluded from analysis
Selective reporting (reporting bias) Low risk Protocol registered on ClinicalTrials.gov
(identifier: NCT00932360). Prespecified
outcomes faithfully reported in study re-
port
Sample size High risk < 50 participants per treatment arm.
Other bias Unclear risk Conflict of interest: 2 authors supported by
DJO (Vista, CA, USA)
Sponsorship: American Physical Therapy
Association and University of Iowa
Study stopped early: no.
Parity of groups at baseline: cross-over
study - no significant differences between
groups in pain at rest or fatigue intensity
before TENS between interventions
Timing of outcome measurement between
groups: identical.
Comparability of cointerventions between
groups: comparable; participants on stable
pharmacological treatment 1 month prior
to study
Fundingdeclarations: grant fromOrthope-
dic Section of American Physical Therapy
Association, Carver College of Medicine
University of Iowa, College of Nursing
University of Iowa (NIH R34 AR060378)
Di Benedetto 1993
Methods Type of study: randomised, controlled, parallel group.
Condition and number of participants randomised: fibromyalgia (Goldenberg criteria:
30 participants)
Groups: TENS (n = 15), SAMe (pharmaceutic approach) (n = 15)
Participants Demographics: n = 30, aged 31-75 years (mean ± SD: 51 ± 9.5 years), 29 women
Setting: not reported.
Inclusion: participants with primary fibromyalgia using the Goldenberg criteria
Exclusion: associated pathological condition (e.g. rheumatoid arthritis, rheumatic dis-
eases, hypothyroidism); severe renal, liver, or cardiovascular diseases; receiving antide-
pressants, corticosteroids, NSAIDs, or a combination during preceding 4 weeks
Withdrawal/dropouts: none.
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Di Benedetto 1993 (Continued)
Interventions Where applied: rehabilitation centre.
Applied by: investigator.
Instructions to participants: not reported.
Duration of intervention: 6 weeks.
TENS
Waveform: rectangular, continuous.
Frequency: 80-100 Hz.
Pulse duration: 70 µs.
Pulse amplitude/intensity: minimum of a ‘pleasant tingling sensation.’
Electrodes: dimensions of the electrodes not reported.
Electrode placement: at 4 tender points chosen by investigator after consultation with
participant
Duration and frequency of Rx: washout out period of 7 days where NSAIDs and neu-
ropsychoactive drugs were not permitted. Paracetamol allowed occasionally. Then each
tender point treated with TENS for 20 minutes. 5 sessions a week for 6 weeks
Device/manufacturer: not reported.
SAMe
Washout out period of 7 days where NSAIDs and neuropsychoactive drugs were not
permitted. Paracetamol allowed occasionally. After this, daily, 1 × 200-mg vial of SAMe
intramuscularly at 8 a.m. and 2 × 200-mg tablets, 1 at 12 noon and 1 at 6 p.m. for 6
weeks
Outcomes Duration of follow-up: during the 6-week intervention period; no post-treatment follow-
up
Outcome: at baseline, after washout period, after 2, 4, and 6 weeks of intervention. Pain
during manual assessment of tenderness (0 = no tenderness, 4 = maximum tenderness)
at C4-C5 and L4-L5, upper borders of trapezius, second costochondral junctions, lateral
epicondyles, supraspinatus origins, upper outer quadrants of buttocks, and medial fat
pads of knees. Total number of tender points and total tender point score (sum of all 14
individual tender point scores) computed at each time point. Pressure pain threshold at
trapezius muscle and elbow measured using digital dolorimeter. Depression and anxiety
scales also recorded
Type of analysis: per protocol.
Statistical analysis: total tender point score and VAS; split plot analysis of variance and
Tukey’s test for multiple comparisons. Mann-Whitney for total number of tender points
and each tender point score
Adverse effects: reported no adverse effects in either group
Notes Country of origin: Italy.
Conflict of interest: not reported.
Sponsorship: BioResearch, Liscate, Italy.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study reported as randomised but method
not described.
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Di Benedetto 1993 (Continued)
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants: not blind.
Care providers administering TENS: not
reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors: not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study and
there were no missing outcome data
Selective reporting (reporting bias) Unclear risk No protocol registered or published. Pre-
specified primary outcomes for pain re-
ported. Additional non-specified post-
study analysis conducted
Sample size High risk < 50 participants per treatment arm.
Other bias Unclear risk Conflict of interest: not reported.
Sponsorship: BioResearch, Liscate, Italy.
Study stopped early: no.
Parity of groups at baseline: yes - no sig-
nificant differences in demographic or pain
data
Timing of outcome measurement between
groups: identical.
Comparability of cointerventions between
groups: not reported; paracetamol intake
allowed
Funding declarations: BioResearch, Lis-
cate, Italy.
Guo 2005
Methods Type of study: randomised, controlled, parallel group.
Condition and number of participants randomised: fibromyalgia (1990 American Soci-
ety of Rheumatology) 66 randomised
3 groups: dermal electrical stimulation (n = 22), electroacupuncture (n = 22), medical
(n = 22)
Participants Demographics: n = 66, age range 42-55 years, 55 women.
Setting: hospital.
Inclusion: fibromyalgia as per diagnostic criteria from 1990 American Society of
Rheumatology, sustained pain over 3 months, minimum 11 tender points among 18
palpated points
Exclusion: history of traumatic injury, mental disorder and rheumatoid disease,
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Guo 2005 (Continued)
polymyalgia rheumatica, myofascial syndrome, chronic fatigue syndrome
Withdrawal/dropouts: authors reported all participants completed study
Interventions Where applied: hospital.
Applied by: not reported.
Instructions to participants: not reported.
Duration of intervention: 20 days followed by 4 days’ rest followed by 20-44 days
TENS (dermal electrical stimulation)
Waveform: continuous.
Frequency: 100 Hz (15 minutes) 2 Hz (15 minutes).
Pulse duration: 6-150 ms.
Pulse amplitude/intensity: comfortable muscle contraction (mean ± SD: 14 ± 3 mA)
Electrodes: not reported.
Electrode placement: at acupoints. 2 pairs of main points selected near most distinct
tendon points: GB 20, GB 21, BL 15, BL 16, BL 17, GB 54, GB30, BL 35, LI 11, LR
8, ST 15, ST 14, and ST 17. Supplementary points HT 7, KI 3, ST 36, PC 6
Duration and frequency of Rx: once a day for 20 days followed by 4 days’ rest then
another 20 days with treatment once per day
Device/manufacturer: Henan Xinxinng 128 Factory.
Electroacupuncture
Waveform: continuous.
Frequency: 100 Hz (15 minutes) 2 Hz (15 minutes).
Pulse duration: 6-150 ms.
Pulse amplitude/intensity: determined based on tolerance of participant
Electrodes: application as per dermal stimulation except with No. 28 filiform needles
inserted deeply. After deqi arrival the G-6085 apparatus was applied
Duration and frequency of Rx: once a day for 20 days followed by 4 days’ rest then
another 20 days with treatment once per day
Device/manufacturer: G-6085 (Qingdao Huasheng Instrument Factory)
Medical group (medication)
Oryzanol, orally, 30 mg 3 times a day, Vitamin B1 orally 30 mg, 3 times a day, Amitripty-
line 10 mg increased by 10 mg a day to 20-30 mg a day taken orally at night for 45 days
Outcomes Duration of follow-up: during intervention period only; 45 days. No post-intervention
follow-up
Outcomes: VAS for pain and accompanied symptoms. Scoring adapted to show 0 = no
pain and complete relief from symptoms to 6 = no change in pain or other symptoms.
Scores were combined to give an effectiveness rating (%)
Type of analysis: per protocol.
Statistical analysis: Chi² test on analgesic effects 45 days post-treatment in each group
Adverse effects: not reported.
Notes Country of origin: China.
Conflict of interest: not reported.
Sponsorship: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Study reported as randomised but method
not described.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants: not blind.
Care providers administering TENS: not
reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors: not reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk Data missing for 22 participants at 6
months’ follow-up, 29 at 12 months, and
37 at 24 months. All participants com-
pleted the study and there were no missing
outcome data at 45 days’ follow-up
Selective reporting (reporting bias) High risk No protocol registered or published. Pre-
specified primary outcomes for pain not
clear. Analysis of some outcomes were not
prespecified in methods. 100-mm VAS
scores converted into 4 arbitrary categories
and data analysed using frequency counts
Sample size High risk < 50 participants per treatment arm.
Other bias Unclear risk Conflict of interest: not reported.
Sponsorship: not reported.
Study stopped early: no.
Parity of groups at baseline: yes; no signif-
icant differences in demographic data, du-
ration of pain, number of pain ’spots,’ or
’accompanied symptoms.’
Timing of outcome measurement between
groups: identical.
Comparability of cointerventions between
groups: not reported
Funding declarations: not reported.
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Lauretti 2013
Methods Type of study: randomised, controlled, parallel group.
Condition and number of participants randomised: fibromyalgia (1990 American Col-
lege of Rheumatology Criteria) 39 randomised
Groups: dual-site TENS (n = 13), one-site TENS (n = 13), placebo TENS (n = 13)
Participants Demographics: n = 39, aged 18-48 years, 34 women.
Setting: University Hospital of Sao Paulo.
Inclusion: aged ≥ 18 years, willing and able to participate, taking amitriptyline 25-50
mg before bedtime at least 3 weeks previously as part of protocol
Exclusion: clinically unstable disease, psychiatric disease other than depression, allergy
to devices, use of beta-blockers
Withdrawal/dropouts: 3 participants in placebo TENS group.
Interventions Where applied: hospital.
Applied by: not reported.
Instructions to participants: not reported.
Duration of intervention: 7 days.
TENS
Waveform: rectangular.
Frequency: 2 and 100 Hz mixed frequency.
Pulse duration: 0.2 ms.
Pulse amplitude/intensity: 60 mA.
Electrodes: dimensions not reported.
Electrode placement: lower back perpendicular to spine at 5th vertebra and centrally
above and below the space between C7 and T1 spinous processes for dual-site TENS
and placebo TENS. Single-site TENS was delivered at worst pain at either of these sites
with placebo TENS delivered at the less painful site
Duration and frequency of Rx: 20 minutes, at 12-hour intervals for 7 consecutive days
Device/manufacturer: TANYX.
Placebo TENS
2 placebo TENS devices did not deliver electrical stimulation but looked similar to active
device
Outcomes Duration of follow-up: during intervention period only; 7 days. No post-intervention
follow-up
Pain outcome: pain relief (VAS 10 cm); reduction in analgesic tablets; quality of sleep
and fatigue
Type of analysis: per protocol (n = 36 analysed).
Statistical analysis: VAS scores and daily diclofenac compared among groups during
day 0 - day 7 using a 2-way ANOVA for repeated measures. Tukey’s honest significant
difference analysis was applied to correct P values for multiple group comparisons
Adverse effects: single-site TENS; “two patients from the single-site TENS group got in
sleep after the device application and complained of muscle sore due to more than 70
minutes active device application;” 4 participants in placebo group and 2 in single-site
TENS group had gastric discomfort from diclofenac
Notes Country of origin: Brazil.
Conflict of interest: not reported.
Sponsorship: Medecell Brasil donated active and placebo TENS devices TANYX
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients assigned to treatments using a
randomised number generator.”
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants: blind. Placebo (no current)
TENS device was used for the placebo
group and for the single-TENS group and
was identical to active devices. Operational
details, including exact instructions to par-
ticipants was not reported
Care providers administering TENS: not
reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors: not reported. Study de-
scribed as “double-blind.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 3/39 participants dropped out from the
study due to absence of symptom relief. 2
of these dropouts were from the placebo
TENS group. Missing data removed from
subsequent analysis, yet these data may be
related to true outcome
Selective reporting (reporting bias) Unclear risk No protocol registered or published. Pre-
specified primary outcomes for pain were
reported
Sample size High risk < 50 participants per treatment arm.
Other bias Unclear risk Conflict of interest: not reported.
Sponsorship: Medecell Brasil donated ac-
tive and placebo TENS devices TANYX
Study stopped early: no.
Parity of groups at baseline: yes; no signifi-
cant differences in demographic data, pain,
or cointerventions (medication)
Timing of outcome measurement between
groups: identical.
Comparability of cointerventions between
groups: rescue mediation taken as outcome
measure; diclofenac 50 mg up to 3 times
daily. Reduction in consumption of drug
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medication in single-site TENS and dual-
site TENS after day 1 of study
Funding declarations: not reported; Mede-
cell Brasil donated active and placebo
TENS devices TANYX
Lofgren 2009
Methods Type of study: randomised, controlled, cross-over.
Condition and number of participants randomised: fibromyalgia (1990 American Col-
lege of Rheumatology Criteria) 32 randomised
Groups: TENS (n = 29 analysed), superficial warmth (n = 28 analysed)
Participants Demographics: n = 32, age (mean ± SD): 41 ± 8.3 years, all women
Setting: University Hospital, Stockholm, Sweden.
Inclusion: age 18-60 years.
Exclusion: drug misuse, serious psychiatric disease, previous experience of using TENS
to alleviate musculoskeletal pain
Withdrawal/dropouts: 2 participants for reasons not related to study
Interventions Where applied: hospital.
Applied by: participants but a physiotherapist instructed the participants where to apply
the electrodes
Instructions to participants: how and where to apply the TENS electrodes
Duration of intervention: 21 days, no washout period between interventions
TENS
Waveform: not reported.
Frequency: 80 Hz.
Pulse duration: not reported.
Pulse amplitude/intensity: strong but not unpleasant level.
Electrodes: 4 electrodes, 3 × 8 cm.
Electrode placement: at sites of pain.
Duration and frequency of Rx: daily at least 30 minutes per session, use as often as
needed for 3 weeks before transfer to thermal stimulator with no washout period
Device/manufacturer: Cefar Primo stimulator (Cefar AB, Malmö, Sweden)
Superficial warmth
Portable thermal electrical stimulation, 40 ± 2 ºC, 4 electrodes (3 × 8 cm), on painful
sites, use for 45 minutes to 2 hours per day for 3 weeks
Outcomes Duration of follow-up: during intervention period only; 21 days. No post-intervention
follow-up
Pain outcome: 0-100 NRS (no pain to worst imaginable) before and after each treatment
session. Pain diaries to report how long pain reduction lasted. Change of ≥ 20 points
(NRS) considered a responder. Fibromyalgia Impact Questionnaire
Type of analysis: ITT and per-protocol.
Statistical analysis: between group differences (Mann Whitney test)
Adverse effects: not reported.
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Notes Country of origin: Sweden.
Conflict of interest: not reported.
Sponsorship: Swedish Rheumatism Association, Department of Rehabilitation
Medicine, Danderyd University Hospital and the Division of Rehabilitation Medicine
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study reported as randomised but method
not described.
Allocation concealment (selection bias) Unclear risk Not described; study was cross-over design.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants: not blind.
Care providers administering TENS: not
blind. Physiotherapist administered both
treatments
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessors: not blind (outcome as-
sessor was the physiotherapist administer-
ing treatments)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 2/32 participants dropped out of the study
for reasons “unrelated to treatment.” In
addition, 1 of the remaining 30 partici-
pants did not complete TENS interven-
tion and 2 participants did not complete
the warmth intervention. An ITT and per-
protocol analysis performed although how
dropout data were handled was unclear
Selective reporting (reporting bias) Unclear risk No protocol registered or published. Pre-
specified primary outcomes for pain re-
ported
Sample size High risk < 50 participants per treatment arm.
Other bias Unclear risk Conflict of interest: not reported.
Sponsorship: Swedish Rheumatism Asso-
ciation, the Department of Rehabilita-
tion Medicine, Danderyd University Hos-
pital and the Division of Rehabilitation
Medicine
Study stopped early: no.
Parity of groups at baseline: yes - cross-over
studywith no significant differences in pain
measures at pre-intervention time points, i.
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e. ’no carry-over effects detected.’
Timing of outcome measurement between
groups: identical.
Comparability of cointerventions between
groups: not reported
Funding declarations: Swedish Rheuma-
tism Association, the Department of Reha-
bilitation Medicine, Danderyd University
Hospital and theDivision ofRehabilitation
Medicine
Mutlu 2013
Methods Type of study: randomised, controlled, parallel group.
Condition and number of participants randomised: fibromyalgia duration > 1 year (1990
American College of Rheumatology Criteria) 66 randomised
Groups: exercise with TENS (n = 33), exercise alone (n = 33)
Participants Demographics: n = 66, age range 32-53 years, all women.
Setting: outpatient clinic (Hospital), Turkey.
Inclusion: fibromyalgia, women, pain duration > 1 year.
Exclusion: rheumatoid arthritis, other rheumatic disease, psychiatric disorder, antide-
pressant treatment, medical conditions preventing exercise training, contraindications
for TENS
Withdrawal/dropouts: 6 (3 from each group).
Interventions Where applied: hospital.
Applied by: not reported.
Instructions to participants: not reported.
Duration of intervention: 12 weeks.
TENS (with exercise)
Waveform: not reported.
Frequency: 80 Hz.
Pulse duration: not reported.
Pulse amplitude/intensity: participant tolerance.
Electrodes: TENS applied to most painful areas (neck, shoulder, back, and hip regions)
Electrode dimensions: not reported.
Duration and frequency of Rx: once every week day in the morning for 30 minutes, for
the first 3 weeks of 12-week exercise programme
Device/manufacturer: Enraf-Nonius, En stim-4 (Netherlands).
Exercise (alone)
40-minute exercise class 3 times per week for 12 weeks that included stretching, strength-
ening, and aerobic exercise
Outcomes Duration of follow-up: during intervention period only; 12 weeks. No post-intervention
follow-up
Pain outcome: baseline, 3 and 12 weeks. Tender point count scores 0-18. Myalgic pain
score (degree of the tenderness at tender points on 4-point scale (0 = no pain, 1 =
mild pain, 2 = moderate pain with verbal exclamation, 3 = severe pain with withdrawal
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Mutlu 2013 (Continued)
reaction). Fibromyalgia Impact Questionnaire, SF-36
Type of analysis: per protocol n = 60 (n = 30 per group) analysed
Statistical analysis: between-group comparisons (Mann Whitney test). Within-group
comparisons (Friedman 2-way ANOVA). Pearson’s Chi² tests with Yates correction were
used for nominal variables
Adverse effects: not reported. 3 participants dropped out due to increase pain (1 from
TENS + exercise group and 2 from exercise alone group)
Notes Country of origin: Turkey.
Conflict of interest: authors declared no conflict of interest
Sponsorship: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study reported as binary block randomised
but method not described
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants: not blind.
Care providers administering TENS: not
blind. Exercise and TENS given by the
same physiotherapist
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors: blind. “The physi-
cian who performs the measurements was
blinded to the participant’s groups.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3/33participants in exercise alone and3/33
participants in the exercise + TENS groups
were lost to follow-up and removed from
the subsequent analysis. Missing outcome
data were balanced across groups with sim-
ilar reasons for loss
Selective reporting (reporting bias) Unclear risk No protocol registered or published. Pre-
specified primary outcomes for pain were
reported
Sample size High risk < 50 participants per treatment arm.
Other bias Unclear risk Conflict of interest: none.
Sponsorship: not reported.
Study stopped early: no.
Parity of groups at baseline: yes; no signif-
icant differences between groups for any
outcome measure
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Mutlu 2013 (Continued)
Timing of outcome measurement between
groups: identical.
Comparability of cointerventions between
groups: not reported; permitted to use sim-
ple analgesics but not NSAIDs or antide-
pressant drugs
Funding declarations: not reported.
ANOVA: analysis of variance; ITT: intention-to-treat; n: number of participants; NRS: numerical rating scale; NSAID: non-steroidal
anti-inflammatory drug; Rx: medical prescription; s: second; SAMe: S-adenosyl-L-methionine; SF-36: 36-item Short Form; TENS:
transcutaneous electrical nerve stimulation; µs: microsecond; VAS: visual analogue scale; PPT: pressure pain threshold.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Arroyo 1993 Not an RCT; experimental study.
Ido 2003 Not an RCT; case series.
Kesiktas 2011 TENS given as a combination of therapies which were given to each of the 3 arms and regarded as 1 single treatment;
therefore, we were unable to isolate effects of TENS from other treatment
Mutlu 2006 Error in search citation; original source does not exist.
Simons 2006 Commentaries of previously published studies. An incorrect title was tagged to this citation. The incorrect title
tagged to the study was “A randomised controlled study on the effect of two different treatments (FREMS AND
TENS) in myofascial pain syndrome,” by Farina S, Casarotto M, Benelle M, Tinazzi M, Fiaschi S, Goldoni M,
Smania N. Europa Medicophysica 2004;40(4):293-301. Excluded because participants were excluded from the
original study if they had clinical signs and symptoms of fibromyalgia
Sunshine 1996 Microcurrent not TENS.
FREMS: frequency-modulated electromagnetic neural stimulation; RCT: randomised controlled trial; TENS: transcutaneous electrical
nerve stimulation.
58Transcutaneous electrical nerve stimulation (TENS) for fibromyalgia in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Characteristics of ongoing studies [ordered by study ID]
Noehren 2015
Trial name or title Fibromyalgia Activity Study with Transcutaneous Electrical Nerve Stimulation (FAST)
Methods Phase II randomised, double-blind, placebo-controlled multicentre clinical trial involving TENS. The initial
phase of study will randomly allocate participants to receive active TENS, placebo TENS, or standard care
(no TENS). After participating in the 1-month random assignment, all participants will receive active TENS
for 1 month. The participants will make 4 visits to the clinic approximately 2 to 3.5 hours each visit. Visits
will entail questionnaires, functional tasks, accelerometry, TENS, pain, and fatigue assessments
Participants Estimated that 360 participants will be enrolled.
Interventions Active TENS, placebo TENS, or standard care (no TENS).
Outcomes Primary aim is to test the effect of the long-term use of TENS on movement-related pain as measured by a
numeric rating scale during 6-minute walk test in women with fibromyalgia with random assignment to 3
treatments: standard care (no TENS), placebo TENS, and active TENS
Starting date ClinicalTrials.gov registration June 2013. Protocol published 2015
Contact information Kathleen A Sluka, PT, PhD.
Notes Protocol published by Noehren 2015 is entitled “Effect of transcutaneous electrical nerve stimulation on pain,
function, and quality of life in fibromyalgia: a double-blind randomised clinical trial” and the ClinicalTrials.
gov identifier is NCT01888640. The study by Dailey 2013 included in this review has been used to inform
the design of this trial
TENS: transcutaneous electrical nerve stimulation.
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Table of results
Reference Details of results for individual studies
Carbonario 2013 Greater reductions in pain intensity when TENS was added to an 8-week programme of aerobic and stretching
exercises. A 30% decrease in pain severity was set as a clinically relevant reduction in pain a priori and they
reported that 30% of 14 participants in the TENS with exercise group achieved this clinically relevant im-
provement and this was significantly greater than 13% of 14 participants in the exercise without TENS group.
However, these percentages equate to 4.2 participants and 1.82 participants respectively, which is illogical. The
mean ± SD reduction in pain intensity was 20 ± 29 mm for TENS and 7.0 ± 37 mm for the without TENS.
TENS had improvement in the Fibromyalgia Impact Questionnaire items for pain, work performance, fatigue,
stiffness, anxiety, and depression and exercise had improvements for morning tiredness and depression
da Silva 2008 TENS group showed significantly less pain after the intervention (mean ± SD: 3.4 ± 2.2 (P < 0.004). Hy-
drotherapy group showed no difference in VAS scores post-intervention (mean ± SD: 6.6 ± 1.5)
Between-group comparisons not reported. Hydrotherapy group showed statistically improvement of the SF-36
total score (P = 0.007) and of the domains physical role (P = 0.002), pain (P = 0.007), vitality (P = 0.001),
social aspects (P = 0.04), and emotional role (P = 0.005). There was also an improvement on the scores of the
domain emotional reactions of the Nottingham Health Profile (P = 0.036). TENS group showed statistically
improvement of the SF-36 total score (P = 0.006) and of the domains functional capacity (P = 0.018), physical
role (P = 0.038), pain (P = 0.001), social aspects (P = 0.02), and emotional role (P = 0.004). There was also an
improvement on the scores of the Nottingham Health Profile total score (P = 0.001) and the domains: energy
level (P = 0.009), pain (P = 0.004), and emotional reactions (P = 0.03). There was also a significant difference
on the Beck Depression Inventory (P = 0.004)
Dailey 2013 A single 30-minute treatment of active TENS reduced pain intensity (VAS) on movement compared with
placebo TENS with the mean ± SD difference in VAS scores (100 mm) before and during intervention being
11.1 ± 2.6 mm (95% CI 5.9 to 16.3) for TENS and 2.3 ± 2.6 mm (95% CI 2.4 to 7.7) for placebo TENS
(Dailey 2013). There were no significant differences between TENS and placebo TENS for pain at rest. TENS
reduced pain intensity (VAS) on movement compared with no-TENS (2.6 ± 2.5 mm (95% CI 2.8 to 7.5)
). There were no significant differences between TENS and no TENS for pain at rest. PPT in the cervical
region was significantly increased by active TENS versus control but not versus placebo (P < 0.05). Lumbar
region PPT was significantly increased with active TENS versus placebo and control (P < 0.05). PPTs over the
anterior tibialis (n = 36) were significantly increased with active TENS versus control (P < 0.05). Fatigue with
movement during the 6-minute walk test was significantly reduced for active TENS compared with placebo
TENS (P < 0.005) and for active TENS compared with no TENS (P < 0.001). No significant differences
between any groups for range of motion, single leg stance, sit-to-stand test, 6-minute walk test. This study had
the lowest risk of bias of the studies included in our review
Di Benedetto 1993 The total number of tender points decreased significantly from 10 to 5 only in the SAMe group (P < 0.01) and
the 2 groups differed significantly at the end of treatment (P = 0.05) in the total number of tender points (P < 0.
05). The total tender point score improved significantly (P < 0.01) during SAMe treatment. The SAMe group
also improved significantly in the subjective evaluation and psychiatric rating scales. No significant differences
were shown for pain in the TENS group. Within-group statistics reported for other outcomes. SAMe produced
reductions in scores for both the Hamilton Rating Scale for Depression and the Hamilton Rating Scale for
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Table 1. Table of results (Continued)
Anxiety and by day 14 of treatment. TENS only produced a reduction in theHamilton Rating Scale for Anxiety
score at the end of treatment only
Guo 2005 There were no significant differences between the TENS and electroacupuncture groups (P > 0.05) but both
showed significantly positive differences compared with the medical group (P < 0.01). Data were reported for
6, 12, and 24 months. All participants completed the study
Lauretti 2013 Mean ± SD pain intensity (100-mm VAS) decreased from 85 ± 20 mm at baseline to 43 ± 20 mm after 1 week
of dual-site TENS (reduction of 49.4%) and decreased from 85 ± 10 mm at baseline to 60 ± 10 mm after 1
week of single-site TENS (pain reduction of 29%). Placebo TENS decreased from 82 ± 20 mm at baseline
to 80 ± 20 mm after 1 week (pain reduction of 2.5%). There were statistically significant differences between
groups (P < 0.02). Daily consumption of diclofenac 50 mg was statistically significant between groups (P < 0.
05) and lower for both the single- and dual-site TENS compared with placebo-TENS. Quality of sleep was
improved with dual-site TENS (10 participants) and single-site TENS (8 participants) and worsened in the
placebo TENS group (n = 4; P < 0.05). Quality of fatigue was improved with dual-site TENS (7 participants)
and single-site TENS (5 participants) but not with placebo-TENS (n = 0; P < 0.05)
Lofgren 2009 Between-group differences for pain intensity were not significant. ITT analysis: 10 responders reported a
reduction of ≥ 20 points with thermal therapy and 10 responded in the same way with TENS. Per-protocol
analysis: 42% of 24 participants responded to warmth and 36% of 28 responded to TENS (difference between
groups was not statistically significant) (P = 0.66). 4 participants were considered responders to both. No
difference in duration of pain relief between groups
Mutlu 2013 The exercise with TENS group showed a more significant improvement in myalgic pain at the end of the 3rd
week than the exercise alone group but this decrease in pain was similar in both groups by the end of week 12.
Scores in the Fibromyalgia Impact Questionnaire and SF-36 improved significantly in both groups by the end
of the 3rd week. 6 withdrawals reported; 3 from each group
CI: confidence interval; SAMe: S-adenosyl-L-methionine; SD: standard deviation; SF-36: 36-item Short Form; PPT: pressure pain
threshold; TENS: transcutaneous electrical nerve stimulation; VAS: visual analogue scale.
A P P E N D I C E S
Appendix 1. Methodological considerations for chronic pain
There have been several recent changes in how the efficacy of conventional and unconventional treatments is assessed in chronic painful
conditions. The outcomes are now better defined, particularly with new criteria for what constitutes moderate or substantial benefit
(Dworkin 2008); older trials may only report participants with ’any improvement.’ Newer studies tend to be larger, avoiding problems
from the random play of chance. Newer studies also tend to be of longer duration, up to 12 weeks, and longer studies provide a more
rigorous and valid assessment of efficacy in chronic conditions. New standards have evolved for assessing efficacy in neuropathic pain,
and we are now applying stricter criteria for the inclusion of studies and assessment of outcomes, and are more aware of problems that
may affect our overall assessment. To summarise some of the recent insights that must be considered in this new review:
1. Pain results tend to have a U-shaped distribution rather than a bell-shaped distribution. This is true in acute pain (Moore
2011b; Moore 2011c), back pain (Moore 2010d), and arthritis (Moore 2010c), as well as in fibromyalgia (Straube 2010); in all cases,
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mean results usually describe the experience of almost no-one in the trial. Data expressed as means are potentially misleading, unless
they can be proven to be suitable.
2. As a consequence, we have to depend on dichotomous results (the person either has or does not have the outcome) usually from
pain changes or participant global assessments. The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials
(IMMPACT) group has helped with their definitions of minimal, moderate, and substantial improvement (Dworkin 2008). In
arthritis, studies of less than 12 weeks’ duration, and especially those shorter than eight weeks, overestimate the effect of treatment
(Moore 2010c); the effect is particularly strong for less-effective analgesics, and this may also be relevant in neuropathic-type pain.
3. The proportion of people with at least moderate benefit can be small, even with an effective medicine, falling from 60% with an
effective medicine in arthritis to 30% in fibromyalgia (Moore 2009; Moore 2010c; Moore 2013b; Moore 2014b; Straube 2008;
Sultan 2008). One Cochrane Review of pregabalin in neuropathic pain and fibromyalgia demonstrated different response rates for
different types of chronic pain (higher in diabetic neuropathy and postherpetic neuralgia and lower in central pain and fibromyalgia)
(Moore 2009). This indicates that different neuropathic pain conditions should be treated separately from one another, and that
pooling should not be done unless there are good grounds for doing so.
4. Individual participant analyses indicate that people who get good pain relief (moderate or better) have major benefits in many
other outcomes, affecting quality of life in a significant way (Moore 2010b; Moore 2014b).
5. Imputation methods such as last observation carried forward, used when participants withdraw from clinical trials, can overstate
drug efficacy especially when adverse event withdrawals with drug are greater than those with placebo (Moore 2012b).
Appendix 2. Search strategies
CENTRAL
#1 MESH DESCRIPTOR TRANSCUTANEOUS ELECTRIC NERVE STIMULATION EXPLODE ALL TREES 1292
#2 ((TENS or TNS or ENS)):TI,AB,KY 1095
#3 ((Transcutaneous electric* nerve stimulation or transcutaneous nerve stimulation)):TI,AB,KY 1374
#4 ((Electric* nerve stimulation or electrostimulation therap* or electro-stimulation therap*)):TI,AB,KY 1496
#5 ((Electric* nerve therap* or electroanalgesi*)):TI,AB,KY 24
#6 #1 OR #2 OR #3 OR #4 OR #5 2508
#7 MESH DESCRIPTOR Fibromyalgia EXPLODE ALL TREES 616
#8 Fibromyalgi*:TI,AB,KY 1276
#9 Fibrositis:TI,AB,KY 60
#10 #7 OR #8 OR #9 1313
#11 #6 AND #10 23
MEDLINE
1 exp TRANSCUTANEOUS ELECTRIC NERVE STIMULATION/ (6585)
2 (TENS or TNS or ENS).ti. (625)
3 (TENS or TNS or ENS).ab. (9722)
4 (Transcutaneous electric* nerve stimulation or transcutaneous nerve stimulation).mp. [mp=title, abstract, original title, name of
substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary
concept word, unique identifier] (4271)
5 (Electric* nerve stimulation or electrostimulation therap* or electro-stimulation therap*).mp. [mp=title, abstract, original title, name
of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary
concept word, unique identifier] (4613)
6 (Electric* nerve therap* or electroanalgesi*).mp. [mp=title, abstract, original title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier] (177)
7 or/1-6 (16370)
8 exp Fibromyalgia/ (6940)
9 Fibromyalgi$.tw. (6932)
10 Fibrositis.tw. (419)
11 or/8-10 (8279)
12 11 and 7 (38)
13 randomised controlled trial.pt. (414789)
14 controlled clinical trial.pt. (90619)
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15 randomized.ab. (311705)
16 placebo.ab. (158104)
17 drug therapy.fs. (1852228)
18 randomly.ab. (220170)
19 trial.ab. (322366)
20 groups.ab. (1389663)
21 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 (3518483)
22 exp animals/ not humans.sh. (4236009)
23 21 not 22 (2997289)
24 12 and 23 (23)
Embase
1 exp TRANSCUTANEOUS ELECTRIC NERVE STIMULATION/ (6451)
2 (TENS or TNS or ENS).ti. (990)
3 (TENS or TNS or ENS).ab. (13947)
4 (Transcutaneous electric* nerve stimulation or transcutaneous nerve stimulation).mp. [mp=title, abstract, heading word, drug trade
name, original title, device manufacturer, drug manufacturer, device trade name, keyword] (7074)
5 (Electric* nerve stimulation or electrostimulation therap* or electro-stimulation therap*).mp. [mp=title, abstract, heading word, drug
trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] (14512)
6 (Electric* nerve therap* or electroanalgesi*).mp. [mp=title, abstract, headingword, drug trade name, original title, devicemanufacturer,
drug manufacturer, device trade name, keyword] (372)
7 or/1-6 (31380)
8 exp Fibromyalgia/ (15524)
9 Fibromyalgi$.tw. (12305)
10 Fibrositis.tw. (472)
11 or/8-10 (16669)
12 11 and 7 (228)
13 random$.tw. (1081045)
14 factorial$.tw. (27590)
15 crossover$.tw. (57286)
16 cross over$.tw. (25547)
17 cross-over$.tw. (25547)
18 placebo$.tw. (237374)
19 (doubl$ adj blind$).tw. (167989)
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20 (singl$ adj blind$).tw. (17561)
21 assign$.tw. (285981)
22 allocat$.tw. (103689)
23 volunteer$.tw. (206563)
24 Crossover Procedure/ (46997)
25 double-blind procedure.tw. (235)
26 Randomized Controlled Trial/ (403169)
27 Single Blind Procedure/ (22055)
28 or/13-27 (1693697)
29 (animal/ or nonhuman/) not human/ (5030350)
30 28 not 29 (1503865)
31 12 and 30 (59)
PsycINFO
1 (TENS or TNS or ENS).ti. (122)
2 (TENS or TNS or ENS).ab. (1474)
3 (Transcutaneous electric* nerve stimulation or transcutaneous nerve stimulation).mp. [mp=title, abstract, heading word, table of
contents, key concepts, original title, tests & measures] (313)
4 (Electric* nerve stimulation or electrostimulation therap* or electro-stimulation therap*).mp. [mp=title, abstract, heading word, table
of contents, key concepts, original title, tests & measures] (363)
5 (Electric* nerve therap* or electroanalgesi*).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests
& measures] (13)
6 exp Fibromyalgia/ (1517)
7 Fibromyalgi$.tw. (2633)
8 Fibrositis.tw. (39)
9 or/6-8 (2681)
10 or/1-5 (1664)
11 9 and 10 (9)
AMED
1 exp TRANSCUTANEOUS ELECTRIC NERVE STIMULATION/ (654)
2 (TENS or TNS or ENS).ti. (222)
3 (TENS or TNS or ENS).ab. (319)
4 (Transcutaneous electric* nerve stimulation or transcutaneous nerve stimulation).mp. [mp=abstract, heading words, title] (755)
5 (Electric* nerve stimulation or electrostimulation therap* or electro-stimulation therap*).mp. [mp=abstract, heading words, title]
(768)
6 (Electric* nerve therap* or electroanalgesi*).mp. [mp=abstract, heading words, title] (9)
7 or/1-6 (843)
8 exp Fibromyalgia/ (1611)
9 Fibromyalgi$.tw. (1797)
10 Fibrositis.tw. (20)
11 or/8-10 (1802)
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12 11 and 7 (8)
CINAHL
S21 S11 AND S20
S20 S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19
S19 (allocat* random*)
S18 (MH “Quantitative Studies”)
S17 (MH “Placebos”)
S16 placebo*
S15 (random* allocat*)
S14 (MH “Random Assignment”)
S13 (Randomi?ed control* trial*)
S12 (singl* blind* ) or (doubl* blind* ) or (tripl* blind* ) or (trebl* blind* ) or (trebl* mask* ) or (tripl* mask* ) or (doubl* mask* ) or
(singl* mask* )
S11 S6 AND S10
S10 S7 OR S8 OR S9
S9 Fibrositis
S8 Fibromyalgi*
S7 (MH “Fibromyalgia”)
S6 S1 OR S2 OR S3 OR S4 OR S5
S5 (Electric* nerve therap* or electroanalgesi*)
S4 (Electric* nerve stimulation or electrostimulation therap* or electro-stimulation therap*)
S3 (Transcutaneous electric* nerve stimulation or transcutaneous nerve stimulation)
S2 TI ( (TENS or TNS or ENS) ) OR AB ( (TENS or TNS or ENS) )
S1 (MH “Transcutaneous Electric Nerve Stimulation”)
Web of Science
#14 #13 AND #9
DocType=All document types; Language=All languages;
#13 #12 OR #11 OR #10
DocType=All document types; Language=All languages;
#12 TOPIC: ((((singl* OR doubl* OR trebl* OR tripl*) SAME (blind* OR mask*))))
DocType=All document types; Language=All languages;
#11 TOPIC: (((controlled clinical trial OR controlled trial OR clinical trial OR placebo)))
DocType=All document types; Language=All languages;
#10 TOPIC: (((randomised OR randomized OR randomly OR random order OR random sequence OR random allocation OR
randomly allocated OR at random OR randomized controlled trial)))
DocType=All document types; Language=All languages;
#9 #8 AND #3
DocType=All document types; Language=All languages;
#8 #7 OR #6 OR #5 OR #4
DocType=All document types; Language=All languages;
#7 TOPIC: ((“Electric* nerve therap*” or electroanalgesi*))
DocType=All document types; Language=All languages;
#6 TOPIC: ((“Electric* nerve stimulation” or “electrostimulation therap*” or “electro-stimulation therap*”))
DocType=All document types; Language=All languages;
#5 TOPIC: ((“Transcutaneous electric* nerve stimulation” or “transcutaneous nerve stimulation”))
DocType=All document types; Language=All languages;
#4 TOPIC: ((TENS or TNS or ENS))
DocType=All document types; Language=All languages;
#3 #2 OR #1
DocType=All document types; Language=All languages;
#2 TOPIC: (Fibrositis)
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DocType=All document types; Language=All languages;
#1 TOPIC: (Fibromyalgi*)
DocType=All document types; Language=All languages; Web of Science
LILACS
(TENS or TNS or ENS) or (Transcutaneous electric$ nerve stimulation or transcutaneous nerve stimulation) or (Electric$ nerve
stimulation or electrostimulation therap$ or electro-stimulation therap$) or (Electric$ nerve therap$ or electroanalgesi$) [Words] and
Fibromyalgi$ or Fibrositis [Words]
PEDro
1. Abstract & Title:“electrical stimulation” pain
2. Therapy: electrotherapies, heat and cold
3. Problem: pain
4. Method: Clinical Trial
SPORTDiscus (EBSCO)
1. S1 and S2 and S3
2. Transcutaneous electric* nerve stimulation or transcutaneous nerve stimulation neoplasm*
3. Electric* nerve stimulation or electrostimulation therap* or electro-stimulation therap*
4. Electric* nerve therap* or electroanalgesi*
5. exp Fibromyalgia/
6. Fibromyalgi$.tw.
7. Fibrositis.tw.
WH A T ’ S N E W
Last assessed as up-to-date: 18 January 2017.
Date Event Description
3 October 2017 Review declared as stable See Published notes.
C O N T R I B U T I O N S O F A U T H O R S
• MIJ and LSC led the design of the review protocol. All authors contributed to the writing of the protocol.
• LSC developed the search strategy and MIJ, GJ, and CAP implemented the search strategy with the PaPaS Group’s Information
Specialist.
• CAP and MIJ screened articles for eligibility.
• LSC and CAP managed data and extracted data in the full review.
• GPH, CAP, GJ, and MIJ were responsible for data analysis.
• All authors completed the full review and will be responsible for updating the review in future.
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D E C L A R A T I O N S O F I N T E R E S T
MIJ: none known. MIJ is a physiologist and authored a book “TENS. Research to Clinical Practice” in 2014. He is also involved in the
professional training of healthcare practitioners about the use of TENS.
LSC: none known. LSC is a qualified physiotherapist and is involved in the professional training of physiotherapists about the use of
TENS.
GPH: none known.
GJ: none known.
CAP: none known. CAP is a qualified physiotherapist and is involved in the professional training of physiotherapists about the use of
TENS.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We extended the GRADE methods to include the potential to downgrade by three levels at once.
N O T E S
At publication, the authors are not aware of any potentially relevant studies likely to change the conclusions that are due to be published
in the near future. Therefore, this review has now been stabilised for five years. If appropriate, we will update the review earlier if new
evidence likely to change the conclusions is published, or if standards change substantially which necessitate major revisions.
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